Proliferating Fibroblasts and HeLa Cells Co-cultured *In Vitro* Reciprocally Influence Growth Patterns, Protein Expression, Chromatin Features and Cell Survival

JOHN G. DELINASIOS[1], FLORA ANGELI[1], GEORGE KOUMAKIS[1], SHANT KUMAR[2], WEN-HUI KANG[2], GIGLIOLA SICA[3], FORTUNATA IACOPINO[3], GINA LAMA[3], SERGIO LAMPRECHT[4], INA SIGAL-BATIKOFF[4], GEORGE T. TSANGARIS[5], CHRISTOS D. FARFARELOS[6], MARIA C. FARFARELOS[7], ELEFTHERIOS VAIRAKTARIS[8], STAVROS VASSILIOU[8] and GEORGE J. DELINASIOS[1]

[1]International Institute of Anticancer Research, Kapandriti, Attiki, Greece;
[2]Department of Experimental Medicine, Medical School, University of Manchester, Manchester, U.K.;
[3]Institute of Histology and Embryology, "A. Gemelli" Faculty of Medicine,
Catholic University of the Sacred Heart, Rome, Italy;
[4]Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beersheba, Israel;
[5]Proteomics Research Unit, Biomedical Research Foundation of the Academy of Athens, Athens, Greece;
[6]Department of General Surgery, Metaxa Cancer Hospital, Piraeus, Greece;
[7]Department of Plastic Surgery, Metaxa Cancer Hospital, Piraeus, Greece;
[8]Department of Maxillofacial Surgery, Attikon University Hospital, Athens, Greece

Abstract. *Aim: to identify biological interactions between proliferating fibroblasts and HeLa cells in vitro. Materials and Methods: Fibroblasts were isolated from both normal and tumour human tissues. Coverslip co-cultures of HeLa and fibroblasts in various ratios with medium replacement every 48 h were studied using fixed cell staining with dyes such as Giemsa and silver staining, with immunochemistry for Ki-67 and E-cadherin, with dihydrofolate reductase (DHFR) enzyme reaction, as well as live cell staining for non-specific esterases and lipids. Other techniques included carmine cell labeling, autoradiography and apoptosis assessment. Results: Under conditions of feeding and cell: cell ratios allowing parallel growth of human fibroblasts and HeLa cells, co-cultured for up to 20 days, a series of phenomena occur consecutively: profound affinity between the two cell types and exchange of*

small molecules; encircling of the HeLa colonies by the fibroblasts and enhanced growth of both cell types at their contact areas; expression of carbonic anhydrase in both cell types and high expression of non-specific esterases and cytoplasmic argyrophilia in the surrounding fibroblasts; intense production and secretion of lipid droplets by the surrounding fibroblasts; development of a complex net of argyrophilic projections of the fibroblasts; E-cadherin expression in the HeLa cells; from the 10th day onwards, an increasing detachment of batches of HeLa cells at the peripheries of colonies and appearance of areas with many multi-nucleated and apoptotic HeLa cells, and small HeLa fragments; from the 17th day, appearance of fibroblasts blocked at the G_2-M phase. Co-cultures at approximately 17-20 days display a cell-cell fight with foci of (a) sparse growth of both cell types, (b) overgrowth of the fibroblasts and (c) regrowth of HeLa in small colonies. These results indicate that during their interaction with HeLa cells in vitro, proliferating fibroblasts can be activated against HeLa. This type of activation is not observed if fibroblast proliferation is blocked by contact inhibition of growth at confluency, or by omitting replacement of the nutrient medium. Conclusion: The present observations show that: (a) interaction between proliferating fibroblasts and HeLa cells in vitro drastically influences each other's protein expression, growth pattern, chromatin features and survival; (b) these functions depend on the fibroblast/HeLa ratio, cell topology (cell-cell contact and the architectural pattern developed during co-culture) and frequent medium change, as prerequisites for fibroblast proliferation; (c) this co-culture

Correspondence to: John G. Delinasios, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Road, Kapandriti (POB 22), Attiki 19014, Greece. Tel: +30 2295052945, Tel/Fax: +30 2295053389, e-mail: editor@iiar-anticancer.org

model is useful in the study of the complex processes within the tumour microenvironment, as well as the in vitro reproduction and display of several phenomena conventionally seen in tumour cytological sections, such as desmoplasia, apoptosis, nuclear abnormalities; and (d) overgrown fibroblasts adhering to the boundaries of HeLa colonies produce and secrete lipid droplets.

Before the development of its own environment, at a very initial stage of its existence, a tumour may start from a single cell, which, as a result of an intrinsic carcinogenic process, has undergone specific genome alterations and creates a small colony by successive abnormal and unrestrained divisions (1). This rampant behaviour is challenged by the homeostatic/immune surveillance mechanisms of the organism and, if it is successfully confronted, the malignant cells are eradicated. If not, the small bundle of malignant cells gives rise to a tumour, which *per se* establishes its own microenvironment and "tumour homeostasis". Escape of cancer cells from the homeostatic immune control, one of the "hallmarks of cancer" (2, 3), has long since been suggested as an initial phenomenon in cancer development (4, 5). As these malignant cells mingle with other cell types, such as normal fibroblasts, that grow in parallel with them to form part of the tumour microenvironment (TME), the study of interactions between cancer cells and fibroblasts, as well as the role of fibroblasts in tumour progression have attracted a great interest (6-12).

Within the tumour stroma microenvironment, fibroblast-like cells comprise a large variety of cells with a predominant spindle-shaped *in vitro* morphology (pericytes, endothelial cells, "angiogenic cells", capillary tube cells, myofibroblasts, adipocytes). A particular type of stromal fibroblast, the cancer-associated or tumour-associated fibroblasts (CAFs or TAFs respectively) or myofibroblast within the tumour, has been shown to affect extracellular matrix (ECM) remodeling and activation of various mechanisms for supporting cancer cell growth (11, 13-16), and eventually invasion and metastasis (13, 16, 17-21).

The growth or invasion-supportive activity of CAFs has been associated with altered, induced or suppressed expression of a large variety of genes in both cancer cells and CAFs (17, 21-41). These activities have been described in co-cultures and histological samples containing adjacent cancer cells and stromal fibroblasts. The proportion of CAFs expressing each of these activities may differ in different samples or in different areas of the tumour. Thus, there is reasonable evidence pointing to the existence of multiple subpopulations of stromal fibroblasts (including CAFs) displaying heterogeneity regarding their gene expression and functions (27, 36, 42-49).

The growth of stromal fibroblasts within a tumour and, mostly, at its periphery (42, 50), as well as the creation of a unique ECM extracellular matrix (9, 51), as a response to cancer initiation and growth, has been termed reactive stroma, stromagenesis, fibrovascular stroma, stromal reaction, fibromyxoid reaction, fibrosis, desmoplastic reaction, and the phenomenon 'desmoplasia' (from the Greek for creation of chains) (9, 14, 42, 52-55). Desmoplasia has been suggested as a host defense against neoplasia (6, 46, 52, 56-60), and histologically observed desmoplasia has often been associated with aggressive tumours and poor prognosis (49, 61-64).

Since desmoplasia differs widely by tumour type (49, 64, 65) and since it may have opposing or supporting effects in different areas of the same tumour (39, 48, 66-73), a definitive description of its role in neoplasia has not been given. It remains unclear whether desmoplasia is a homeostatic response to cancer, or is caused by the cancer cells themselves (74). An interplay between desmoplasia, the inflammatory process and cancer has also been the focus of continuing studies indicating the possibility that desmoplasia may represent a post-inflammatory/pre-neoplastic condition (23, 75-77).

In tumour biopsy sections, CAFs can be seen around tumour cell nests, at the tumour periphery (29, 53, 78-81), but mostly at the invasive front (48, 82-84). Therefore, there is adequate evidence to show that heterogeneous distribution of stroma exists in a tumour's microenvironment (29, 65, 68, 85), contributing further to cancer heterogeneity.

The identification of CAFs in most studies has been based mainly on the expression of alpha smooth muscle actin (α-SMA), but also on fibroblast-specific protein 1 (FSP-1), vimentin or desmin (25, 68, 86, 87). A comprehensive description and definition of CAFs has been suggested that should also include the study of several ultrastructural features (88, 89) and gene-expression profiles (37, 90, 91). Thus, the definition of CAFs through a single marker may be inaccurate due to their high heterogeneity within the tumour stroma (53, 68, 70, 82, 92).

Although CAFs do not display somatic mutations, epigenetic changes have been observed, and are thought to regulate part of the gene expression of CAFs (93, 94).

The origin of CAFs remains unclear (45) since there are indications that they may be derived from resident fibroblasts, pericytes, mesenchymal stem cells, endothelial cells, carcinoma cells, epithelial cells, smooth muscle cells, bone marrow-derived cells, fibrocytes or adipocytes (53, 95-99). It should be noted that fibroblasts stimulated by various cytokines produced by cancer cells [such as transforming growth factor α (TGFα), transforming growth factor β (TGFβ), epidermal growth factor (EGF), β epidermal growth factor (EGF), platelet-derived growth factor (PDGF), tumour necrosis factor alpha, Interleukin 1 (IL-1), IL-6, IL-8] are transformed to myofibroblasts (90, 100, 101) located close to cancer cells (101). This effect of cancer cells on fibroblasts has also been suggested to be responsible for the desmoplastic reaction in tumours (74, 101).

Terms, such as multipotent mesenchymal stem cells, are extensively used in the literature to declare heterogeneous populations of fibroblast-like cells isolated from various tissues. These cells exert a variety of effects based mainly on their "flexibility" in expressing certain genes, thus facilitating specific final phenomena, including transdifferentiation (102-104). Remarkably, CAFs, myofibroblasts, mesenchymal stem cells and fibroblasts have more similarities than previously recognised (98, 105-109). These include non-tumourigenicity and no or very limited acquisition of chromosomal aberrations (110); immunoregulatory or immunosuppressive properties (75, 111-113); tissue-repair mechanisms, including dermis, tendon and bone cartilage (114, 115); adaptive nature and potential for differentiation (103, 104, 116-118); affinity for cancer cells both *in vitro* and *in vivo* (119, 120-122); and antiproliferative effects (123, 124).

The ratio of CAFs to non-CAFs varies not only by tumour type but also within the same type of tumour in different patients (1, 11, 21, 47, 68, 74, 82, 87, 125-133), therefore justifying the question of the role of non-CAFs in the desmoplastic reaction (46, 51, 72, 131, 133). Only a small fraction of fibroblasts in breast cancer is converted into myofibroblasts (127, 128). In addition, fibroblasts and mesenchymal stromal cells of various origins have considerable *in vitro* heterogeneity regarding morphology (9, 43, 134, 135), response to host-tumour cell-cell interactions (82), phenotype (9, 103, 136, 137), gene-expression profile (7, 9, 27, 46, 135, 138) and immunomodulatory capacity (138, 139). Fibroblasts may remarkably exhibit heterogeneous properties even within the same organ (46, 139-141). Furthermore, stromal fibroblasts from different locations within a tumour may have different properties (39, 48, 68-72, 82, 91). CAFs in endometrial tumour biopsy sections from different patients also exhibit wide variations in the expression of mesenchymal cell markers, growth factors, cell cycle regulators, steroid hormones and angiogenesis factors (78).

Normal fibroblasts *in vitro* are typically senescent spindle-shaped cells exhibiting high mobility, contact inhibition of growth, chromosomal stability in culture (134, 142-145) and absence of malignant cellular phenotypes (15). They have been shown to be prone to alterations of their gene-expression profile during their involvement in embryonic development (53, 146), mammary gland formation and breast morphogenesis (25, 53, 147, 148), endometrial cellular physiological processes (149), prostate development (150) and wound healing and tissue repair (86, 87, 115, 136, 151). During these processes, normal fibroblasts are converted into myofibroblasts (10, 74, 86, 149, 152-154) that exhibit elevated levels of collagen, α-SMA and the ED-A splice variant of fibronectin (25, 87) and of a number of other proteins (150, 155); or transdifferentiate into various final cell types (104, 156). These alterations cease to exist after normal functions have been established or regained and myofibroblasts

disappear by apoptosis (86, 149, 152, 157). Thus, in a normal healthy organism, fibroblasts act as infrastructural elements, as regulators of organ development and as guardian of tissue architecture and homeostasis (74, 123, 150, 152, 158-161). If fibroblasts maintain these fundamental properties within the desmoplastic reaction, it seems reasonable to consider that their presence and growth are involved in the defense mechanism against cancer (46, 51-54, 58, 59, 162). However, there is evidence suggesting that in the tumour microenvironment, at least some of the stromal fibroblasts undertake a supportive role in tumour growth and metastasis (10, 12, 13, 16, 33, 37, 39, 43, 47, 53, 72, 90, 96, 152, 163-178). Notably, α-SMA-positive myofibroblasts were shown to be supportive of tumour invasion and angiogenesis (39, 72, 179), while α-SMA-negative fibroblasts were inhibitory.

Although there are extensive experimental indications of a tumour-suppressing (inhibitory) action of certain fibroblasts (including mesenchymal stem cells) *in vitro* (6, 10, 12, 58, 124, 161, 164, 180-230) or *in vivo* (58-60, 122, 123, 189, 206, 225, 228, 231-243) (excluding fibroblasts with specific gene manipulations), the mechanisms involved and the final outcome of suppressive effects are still obscure.

It should also be mentioned that the regulation of differentiation and proliferation of cancer cells towards more physiological histological patterns, as well as the reversion of the malignant phenotype by normal fibroblasts, has been described in several studies (147, 180, 206, 244-249). Regulatory effects on cancer progression have also been ascribed to stromal endothelial cells (250).

The above discussion underlines the meaning of 'fibroblast plasticity' (92). However, the precise conditions under which fibroblasts, as a highly heterogeneous compartment of a tumour, may become supportive, inhibitive or catastrophic for tumour cell growth remain unknown (6, 7, 9, 19, 42, 92, 206, 227, 251).

It is certain that fibroblasts should be able to replicate in order to accept signals for the modulation of their own gene expression during S phase, or produce signals for the modulation of genes in epithelial cancer cells. Proliferating fibroblasts do not show α-SMA expression and elevated collagen synthesis, while cells expressing α-SMA express high levels of types I and III collagen mRNA (252). Furthermore, a few studies have stressed the importance of feeding (119, 186, 248, 253) as a means of maintaining fibroblasts in a proliferative state, particularly during their co-culture with cancer cells.

Thus, in continuation of our previous experiments (6, 119, 134, 186) and on the same theoretical basis as previously defined (6, 9), the interactions between HeLa cells and proliferating fibroblasts were studied aiming to describe in detail the influence of one cell type on the behaviour, growth pattern and survival of the other, by applying conventional and specific staining [non-specific esterases, lipid, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), silver staining].

Materials and Methods

Cell lines. Eleven finite stromal fibroblastic cell lines (Table I) were used and are referred to as SF or fibroblasts. Of these, seven have previously been described (134, 142) and four (KA-BC, KR-BC, LA-BC and TONS-57) were developed more recently. Fibroblasts were isolated as previously described (134, 142) and were routinely maintained in McCoy's 5A (Flow Laboratories Inc., Rockville, MD, USA) medium supplemented with 10% fetal bovine serum (Flow Laboratories Inc., Rockville, MD, USA), 10^5 IU/L penicillin, 10^5 µg/L streptomycin and 2 mg/L amphotericin B, at 37˚C and 5% CO_2. The same medium was used in all cell co-culture experiments. All cells were free of bacterial, yeast, fungal and mycoplasma contaminations as tested by ^{3}H-thymidine labeling and autoradiography (254, 255), and mycoplasma antibody assay (256). Cells were not sourced from specimens from patients with HIV or hepatitis. Tissue samples were used after hospital's approval and patient's consent.

All SFs used had replication times of 50-56 h, a chromosomal number of 46 and chromosomal abnormalities including aneuploidy were present in fewer than 4% of the examined metaphases with no persistent chromosomal changes. Their plating efficiencies were very low, requiring a minimum of 1×10^3 to 2×10^3 cells/cm^2 to produce a monolayer.

The HeLa cell line used was produced by cell cloning (257) and had a replication time of 16 h, plating efficiency of 97% and chromosome numbers ranging from 52-88 with ~6% hyperpolyploid cells.

Cell-to-cell interactions in vitro. The basic procedures of studying cell-to-cell interactions *in vitro* have been described elsewhere (134, 142, 186). Since the purpose of the present study was to observe cell interactions for as long as possible, HeLa cells were plated at a density of 5 to 6 cells per 1×1 cm^2 glass coverslip contained in a 32 mm diameter plastic petri dish (Lux, Miles Scientific, Naperville, IL, USA). After 2 to 3 days, colonies of 8-16 HeLa cells were produced and, from that time point, the fibroblasts were added suspended in replacement medium at the desired density. The medium was then changed every second day. Under these conditions, co-cultures were studied for up to 20 days. After every 2 days of co-culture, coverslip-attached cells were washed (×3) in physiological saline and fixed in methanol or 5% paraformaldehyde before staining.

Giemsa staining. Methanol-fixed cells were stained in freshly-prepared Giemsa solution in a buffer prepared by mixing 3 ml 0.1 M citric acid, 8 ml 0.2 M disodium hydrogen phosphate solutions and 80 ml distilled water and adjusting to pH 6.8. Three milliliters of methanol and 6 ml of Giemsa (Gurr R66; BDH Laboratory Supplies, Poole, UK) were then added and the solution was filtered before use. Cells were stained for 20 min, washed in distilled water, in acetone and xylene twice each, and mounted in Canada balsam or DPX (Sigma-Aldrich Biotechnology, St. Louis, MO, USA). Giemsa staining and cell morphology allowed HeLa cells to be differentiated from fibroblasts. HeLa nuclei were pleomorphic and highly hyperchromatic, staining profoundly dark blue with even darker nucleoli and blue cytoplasm, while fibroblast nuclei stained light red-pink with blue nucleoli and very light blue cytoplasm. HeLa cells had an epithelial polygonal morphology, with a nuclear:cytoplasmic ratio of 1:2 to 1:3 and nuclei with 1 to 5 nucleoli. Fibroblasts had a spindle-like morphology, with a flat ellipsoidal nucleus with 1 to 3 nucleoli. They often developed very long projections, and their cytoplasm spread out on glass or plastic surfaces. The nucleus:cytoplasm ratio ranged from 1:5 to 1:14.

Table I. *Finite human fibroblastic cell lines (SF) used in the present study.*

Cell line designation	Site of specimen derivation
AK	Tracheitis
G-EP	CaM - normal breast epidermis
G-L	CaM - metastatic lymph node
KA-BC	CaM - primary tumour
KR-BC	CaM - primary tumour
LA-BC	CaM - primary tumour
PG-M	Chronic mastitis primary lesion
PL-BC	CaM - primary tumour
SE-L	CaM - metastatic lymph node
TONS-F	Tonsillitis
TONS-57	Tonsillitis

CaM: Breast adenocarcinoma with metastases.

Under the microscope, a light green filter was used to accentuate colour contrast. A Zeiss microscope (Carl Zeiss, Jena, Germany) equipped with a digital camera was used for all observations. Methyl Violet (1% in distilled water; BDH Laboratory Supplies, Poole, UK) was also used as a stain to demarcate boundaries of cell colonies.

Carmine marker. Carmine-labeled HeLa cells were prepared by culturing cells in medium containing 0.2% carmine powder (Fisher Scientific Co., Chicago, IL, USA) for 24 h and by washing twice in serum-free medium (186, 259). Carmine appears as tiny dark particles (1-2 µm) in the HeLa cell cytoplasm and is not transferred from one cell to another.

Silver staining. Methanol-fixed cells were silver-stained using the method of Goodpasture and Bloom (260). Staining was monitored under a microscope.

Autoradiography. Metabolic co-operation and cell–cell communication were examined by monitoring tritiated nucleotide exchange between donor (labeled) and recipient cells. The procedure used has been described elsewhere (261). The donor cells were pre-labeled with ^{3}H-uridine (^{3}H-UdR) [0.1 µCi/ml, specific activity (sp. act.) 21 Ci/mmol]; ^{3}H-thymidine (^{3}H-TdR) (0.1 µCi/ml, sp. act. 25 Ci/mmol) (GE Healthcare, Amersham, UK).

Non-specific esterase (NSE) staining. The method described by Nestor and Bancroft (262) using α-naphthyl acetate (Sigma-Aldrich Biotechnology, St. Louis, MO, USA) as substrate at pH 7.1 was adapted with some modifications. Live cells on coverslips were washed 3 times in physiological saline (PS), placed in a 5cm-diameter petri dish and stained under microscopic monitoring at ×25 for approximately 30 min. Fast red TR (Sigma-Aldrich Biotechnology, St. Louis, MO, USA) was used instead of pararosaniline hydrochloride and counterstaining was not used. Cells were then washed in PS, dehydrated in alcohol, fixed in xylene and mounted in DPX. Acetazolamide (20 µM; Sigma-Aldrich Biotechnology, St. Louis, MO, USA) was used to suppress carbonic anhydrase activity (263-265), which was very profound within 5-10 min if acetazolamide was not used. Areas with NSE activity were stained light red to reddish brown.

Lipid staining. Live cells on coverslips were washed gently in PS, transferred into a 5 cm petri dish with 3 ml PS and 0.2 ml dye solution (Sudan Black B, in 1% alcohol; Sigma-Aldrich Biotechnology, St. Louis, MO, USA) and staining was monitored under the microscope at ×25 for 1 h. Cells were gently washed in water and mounted in glycerin jelly. Large fat and lipid droplets stained light blue-grey were seen by adjusting the focus. Lipid droplets in the cytoplasm were stained grey.

Ki-67. The detection of Ki-67 nuclear proliferation antigen was carried out immunohistochemically as previously described (266).

E-Cadherin immunohistochemical staining. Cell monolayers were fixed in methanol for 5 min at 4°C. After rehydration, endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide for 10 min at room temperature. Subsequently, the cells were exposed to normal serum for 30 min to block non-specific binding and incubated with the antibody to E-cadherin (4A2C7 clone, diluted 1:200; ZYMED Laboratories, San Francisco, CA, USA) for 1 h at room temperature. A biotinylated anti-mouse antibody was then added to cells for 45 min and they were treated with the streptavidin-biotin-peroxidase complex solution (Vectastain Elite ABC Kit; Vector Laboratories, Inc., Burlingame, CA, USA) for 30 min. Finally, cells were incubated with 3,3-diaminobenzidine (DAB), monitored for development of a brown reaction product and then slightly counterstained with Mayer's hematoxylin. MCF-7 and Jurkat cells were used as positive and negative controls, respectively. No specific staining was observed when primary antibody was omitted.

Dihydrofolate reductase (DHFR). Cells on coverslips were fixed in 5% paraformaldehyde and stained for DHFR as described by Huennekens *et al*. (267). Counterstaining with Giemsa for 5 min enabled improved observation of the cells.

Apoptosis assessment. Apoptosis in cell monolayers stained with Giemsa was morphologically verified under microscopy by the co-existence of nuclear fragmentation, nuclear abnormalities, micronuclei, apoptotic bodies, cellular membrane blebbing, cytoplasmic vacuolation, condensed basophilic cytoplasm, and cell shrinkage (268, 269).

Results

1. Description of the finite SF cell lines. Derivation of the cell lines used in the experiments is reported in Table I. Some of them (AK, G-EP, G-L, PG-M, PL-BC, SE-L, TONS-F) were produced and described earlier. SF lines originating from tumour tissues were shown to possess a normal karyotype and an uncontrolled growth pattern *in vitro*, with overlapping and piling up of cells (134, 142). Figure 1 shows the morphology of a sparse (a) and a confluent (b) monolayer of normal skin fibroblast cell line G-EP. Figure 2 shows cell overlapping in a cell monolayer of G-L cells isolated from a metastatic lymph node of a patient with breast cancer. The recently developed SF cell lines, KA-BC, KR-BC, LA-BC, presented the same features as PL-BC.

In SF cell line monolayers produced from malignant tissues, two remarkable features were observed: (i) the presence of small cells with darkly stained nuclear fragments during the first and second *in vitro* passages (Figure 3 a, b), diminishing and disappearing at subsequent passages; and (ii) the very rare observation of cells with fragmented nuclei and cells resembling plasma cells with a clock-face pattern of nuclear chromatin (Figure 4).

2. Importance of the HeLa:fibroblast cell ratio and of medium renewal in the growth and behaviour of both cell types. A confluent fibroblast monolayer with contact-inhibited fibroblasts served as a perfect feeder layer for HeLa cells. Even a small inoculum of 1-5 HeLa cells was able to successfully grow on top of the fibroblasts, producing dense colonies of HeLa cells entirely covering and destroying the fibroblast layer with or without replacement of the medium (Figures 5, 6, 7). In contrast, fibroblasts (at any inoculum between 5 and 10^4 cells/ml/1 cm^2) cast over a confluent HeLa cell monolayer did not attach to the HeLa cells. When fibroblasts found any empty space among HeLa cells, they attached and extended, but did not divide. The same effect was observed when a high ratio of HeLa cells:fibroblasts (*e.g.* 20:1; $20×10^3:10^3$ cells) was used. Fibroblasts were able to find space to attach but were very soon contact-inhibited by the HeLa cell population (Figure 8). The same effect was seen when an inoculum of HeLa cells and fibroblasts at ratio of 1:1 with $20×10^3:20×10^3$ cells was used.

When an inoculum ratio of 1:1 with $1×10^3:1×10^3$ to $1×10^4:1×10^4$ HeLa cells:fibroblasts was used, both cell types had space and time to attach and multiply. A high affinity between the two cell types was observed in all modes of co-culture, whether by inoculating HeLa cells and fibroblasts together or separately over a pre-attached non-confluent fibroblast or HeLa cell monolayer, as soon as after 2 days of co-culture. In all these combinations, affinity and absence of overlapping was observed. This phenomenon was observed using the earlier developed fibroblast cell lines (119) and confirmed using all the recently developed cell lines. When medium was not renewed after 2 days of co-culture, fibroblasts stopped replicating, while HeLa cells continued to multiply for three to five days (depending on the initial cell inoculum) before exhausting the medium and lowering the pH below 6.8. The above-described phenomena were observed with all of the finite fibroblast cell lines used in this study.

When an inoculum of 10^5 fibroblasts/ml was cast over a monolayer of small HeLa-cell colonies (6-40 cells in each colony), fibroblasts attached to the entire available glass coverslip surface, but did not overlap HeLa cells, seemingly respecting their territory (Figure 9). However, a rare exception was observed with one cell line, SE-L, in which the fibroblasts showed profound overlapping with HeLa cells (Figure 10).

3. Development of basic procedure for cell-to-cell interactions in vitro. By testing various inocula of fibroblasts, it was found that only inoculation with ≥10^3/cm^2 fibroblasts could provide an actively replicating and motile fibroblast population lasting

Figure 1. *Normal skin fibroblasts (G-EP) isolated from a patient with breast cancer. Giemsa, a: non confluent monolayer, ×25; b: confluent monolayer, ×80.* Figure 2. *Stromal fibroblasts (G-L) isolated from a metastatic lymph node of a patient with breast cancer. Cells show overlapping. Giemsa, ×80.* Figure 3. *Second passage monolayer of stromal fibroblasts (G-L) isolated from a metastatic lymph node of a patient with breast cancer showing darkly stained nuclear fragments, possibly originating from apoptotic cancer cells. Giemsa, a: ×600; b: ×1000.* Figure 4. *First passage monolayer of stromal fibroblasts (PL-BC) isolated from a primary breast adenocarcinoma, showing darkly stained apoptotic cells (arrow) and a clock face-like cell (double arrow) close to a normal fibroblast (asterisk). Giemsa, ×600.* Figure 5. *Confluent fibroblast (PL-BC) feeder layer in co-culture with HeLa cells. HeLa cells (5×10³ in 1 mL medium) were seeded on a 1×1 cm coverslip with a confluent cell monolayer of PL-BC fibroblasts and incubated for 32 h without medium replacement. Adhesion of HeLa on the top of the fibroblasts is apparent. Giemsa, ×20.* Figure 6. *Same culture as shown in the legend to Figure 5, after 72 h without medium replacement. Overgrowth of HeLa on top of the fibroblasts can be seen. Giemsa, ×15.* Figure 7. *Same culture as shown in the legend to Figure 5, after 144 h without medium replacement. A few remaining fibroblasts with faint cytoplasms and nuclei, and shrunk, obviously starving HeLa cells are visible. Giemsa, ×20.*

longer than 12 days, due to the low plating efficiency of these finite cell lines. Considering the feeding antagonism between HeLa cells and fibroblasts and the faster replication time of HeLa cells, in order to avoid exhaustion of the medium (usually occurring after 2-3 days in HeLa cultures and 4-5 days in fibroblast cultures), it was replaced every 2 days in all co-cultures. The procedures using small HeLa-cell colonies at the start of experiments, as described in the Materials and Methods section, were found to secure the parallel growth of both cell types in co-culture for at least 12-16 days (corresponding to approximately 6-8 fibroblast replications and 18-24 HeLa cell replications) at a HeLa cell:fibroblast ratio of about 1:100, without obstruction of fibroblast growth. Thus, a co-culture

system with equal growth and space advantages for both HeLa cells and fibroblasts was established and used throughout the present experiments. It should be noted that during the whole co-culture period studied, the interactions between HeLa cells and fibroblasts caused remarkable fluctuations in the ratio between the two cell types because of inhibition or acceleration of growth of one or the other cell type in focused areas of the cultures.

4. Tropism and affinity between fibroblasts and HeLa cells, and encirclement of HeLa-cell colonies by fibroblasts. It was observed that fibroblasts showed a remarkable tropism and contact guidance towards HeLa cells. They became very elongated and bent, and finally encircled, but did not intrude

Figure 8. *Monolayer of confluent HeLa cells with a contact-inhibited AK fibroblast. A dilute suspension of fibroblasts (10^3 AK cells in 1 mL medium) was seeded over an almost confluent HeLa monolayer on a 1×1 cm coverslip and cells were cultured for 72 h. In such co-cultures, fibroblasts were only able to attach to empty areas of the coverslip surface among HeLa cells but were unable to multiply. Similar results were obtained with all types of normal and stromal fibroblasts used. Giemsa, ×252.* Figure 9. *G-EP fibroblasts and HeLa cell co-culture. An inoculum of 10^5 G-EP fibroblasts in 1 mL medium was cast over a monolayer of small HeLa colonies (6-40 cells/colony) on a 1×1 cm coverslip and cultured for 72 h, with medium replacement at 50 h. Fibroblasts attached to the available glass surface in this image did not overlap the HeLa cells. Giemsa, ×40.* Figure 10. *SE-L fibroblasts and HeLa co-culture. An inoculum of 10^5 SE-L fibroblasts in 1 mL medium was cast over a monolayer of a small HeLa cell (6-40 cells) colony on a 1×1 cm coverslip and cultured for 72 h, with medium replacement at 50 h. A profound overlapping of SE-L cells on HeLa cells can clearly be seen. This phenomenon was not observed with any of the other fibroblastic cells used. Giemsa, ×40.* Figure 11. *Encirclement of HeLa-cell colonies by fibroblasts. An inoculum of 10^3 KR-BC cells in 1 mL medium was cast over a non-confluent monolayer of large and small HeLa-cell colonies and cultured for 50 h. The tendency of the fibroblasts to encircle the small HeLa colonies is obvious. Giemsa, ×120.* Figure 12. *Same co-culture conditions for 72 h as shown in the legend to* Figure 11. *Giemsa, ×140.* Figure 13. *Edge of a HeLa-cell colony surrounded by G-EP fibroblasts. Same conditions as shown in the legend to* Figure 11. *Fine cytoplasmic connections between HeLa cells and fibroblasts are obvious. Giemsa, ×220.*

into the HeLa-cell colonies (Figures 11, 12, 13). The encirclement of HeLa-cell colonies by the fibroblasts was observed from the second day of co-culture. Provided that growth space was available and the medium was replaced every two days, the fibroblasts appeared to show tropism towards small HeLa-cell colonies and encircled them.

While HeLa-cell colonies started to be surrounded by fibroblasts, the nuclei of the peripheral HeLa cells were characteristically positioned far from the fibroblasts and towards the centre of both small (Figure 14) and large (Figures 13, 15 and also Figures 56, 60) colonies. Control HeLa-cell colonies (without fibroblasts) did not demonstrate this behaviour (Figures 16, 17), at least not so markedly in all peripheral HeLa cells as in the co-cultures with fibroblasts. However, when HeLa cells were cast over a dilute monolayer of fibroblasts, the HeLa cells preferentially attached around the fibroblasts, with their nuclei favorably positioned close to the fibroblasts (Figures 18, 19). In such cultures, a remarkable feature of the affinity between the two types of cells was the

development of long cytoplasmic projections of HeLa cells along the edges of the fibroblasts (Figures 20, 21), as also shown by casting a carmine-relabeled HeLa cell suspension over a sparse fibroblast monolayer (Figure 22).

During the parallel growth of the HeLa-cell colonies and the encircling fibroblasts, HeLa cells started piling up in the central areas of the colonies, but also grew actively at the peripheries of the colonies, thus forcing the fibroblasts to become more elongated while being pushed back, without intermixing or overlapping. At this stage, two distinct types of HeLa-cell colonies were observed: (a) colonies with densely growing cells and piling up of cells in the centre, which were encircled by a dense fibroblastic bow, and (b) colonies with densely or loosely growing cells and piling up of cells in the centre but which were not amply encircled by fibroblasts. This phenomenon was previously described using a finite skin fibroblastic cell line (G-EP) (186) and confirmed in the present study for all fibroblastic lines used. Interestingly, this phenomenon shows that even in a single HeLa clone, a variation in colony morphology, as

Figure 14. *Small HeLa-cell colony surrounded by fibroblasts, showing movement of nuclei toward the centre of the colony. An inoculum of 10^3 KR-BC cells in 1 mL medium was cast over a monolayer of sparse HeLa colonies with 4-10 cells and cultured for 24 h. Giemsa, ×140.* Figure 15. *Large HeLa-cell colony surrounded by fibroblasts, showing that all cells at the outer edges of the colonies move their nuclei towards the centre of the colony. An inoculum of 10^5 KR-BC cells in 1 mL medium was cast over a monolayer of large HeLa colonies and cultured for 24 h. Giemsa, ×100. The same phenomenon is also obvious in Figure 13.* Figure 16. *A control HeLa-cell colony. Methyl violet, ×100.* Figure 17. *A large control HeLa-cell colony, not showing nuclear movement of peripheral HeLa cells, with a giant multinucleated cell. Methyl violet, ×40.* Figure 18. *A HeLa cell (left) just attaching to a fibroblast. A dilute suspension of 10^3 HeLa cells in 1 mL medium was cast over a monolayer of dilute AK fibroblasts and cultured for 2 h. Note that the attaching HeLa cell locates its nucleus close to the fibroblast. Giemsa, ×1000.* Figure 19. *HeLa cells attaching to a AK fibroblast. Same conditions as shown in the legend to Figure 18. The affinity between the two types of cells is profound and the movement of the HeLa cell nuclei towards the fibroblasts is apparent after 4 h of co-culture. Giemsa, ×220.* Figure 20. *AK fibroblasts and HeLa co-cultures as shown in the legend to Figure 18. After 6 h of co-culture, the affinity between the two cells is obvious. ×1000.* Figure 21. *Same condition of AK fibroblasts and HeLa co-cultures as shown in the legend to Figure 18, but after 12 h of co-culture. ×1000.* Figure 22. *G-EP fibroblasts and HeLa cells co-cultured for 2 h, as in the legend to Figure 18. HeLa cells were pre-labeled with carmine particles which are apparent in the HeLa-cell cytoplasm as well as on the cytoplasmic projection of the HeLa cell at the edge of the fibroblast (arrow). Giemsa, ×600.*

previously shown (257), may develop, along with a specific response from the fibroblasts.

5. Overgrowth of fibroblasts around HeLa-cell colonies. From the fourth to the eighth day of co-culture, the encircling fibroblasts progressively outgrew and created very dense areas with frequently observed multilayers and crossing growth pattern, indicating uncontrolled growth with loss of contact inhibition, as well as loss of parallel pattern of cell growth (Figures 23, 24).

This phenomenon was evident for normal skin fibroblasts (G-EP), tonsillitis fibroblasts and all cancer-derived SF.

If at this stage the medium was not replaced for 4 days, a HeLa cell layer would appear outside the dense fibroblast layer (Figure 25) and if medium was then renewed, fibroblasts again started to form a second encircling dense bow, as previously described (186). This phenomenon shows (a) the importance of medium replacement since fibroblasts need nutrients for growth and for maintenance of their

Figure 23. *Overgrowth of fibroblasts around HeLa-cell colonies. G-EP cells (10^5 in 1 mL medium) were cast over a monolayer of dilute HeLa-cell colonies (6-10 cells/colony) on a 1×1 cm coverslip and cultured for 7 days with medium replacement every 2 days. Giemsa, ×50.* Figure 24. *Under the same conditions as described in the legend to* Figure 23. *PL-BC fibroblasts were cast over HeLa-cell colonies. Overgrowth of the fibroblasts with criss-cross growth and multilayers can be seen around HeLa-cell colonies. Giemsa, ×60.* Figure 25. *Formation of a HeLa cell layer outside the dense G-EP fibroblast layer surrounding a HeLa-cell colony following four days without renewal of the medium. Co-culture conditions were similar to those given in the legend to Figure 23, with a total co-culture period of 11 days. Giemsa, ×50.* Figure 26. *Polygonal pattern of co-growth of KR-BC fibroblasts with HeLa on the 10th day of co-culture under same conditions as given in the legend to Figure 23. The same polygonal pattern was obtained with all cells used in this study. Silver staining, ×20. Figures of this polygonal pattern are also shown in Figures 31, 37 and 41.* Figure 27. *A focus of abundant multinucleated HeLa cells can be seen located at the boundary of a HeLa-cell colony surrounded by LA-BC fibroblasts, on the 15th day of co-culture. Giemsa, ×120.* Figure 28. *A multinucleated HeLa cell which also contains a small light-pink nucleus, possibly of fibroblastic origin. LA-BC fibroblasts and HeLa, 11 days, Giemsa, ×600.*

capacity to confine HeLa-cell colonies, and (b) the capacity of HeLa cells to pass the dense layer of fibroblasts. When the medium was regularly replaced every 2 days, this phenomenon was not observed.

The pattern of co-growth after approximately the seventh day of co-culture was characterized by the development of a polygonal morphology of HeLa-cell colonies, surrounded by densely growing fibroblasts (Figures 26, 41). The width of the fibroblast area around the HeLa-cell colonies seemed to depend on the initial cell-to-cell ratio and cell number, the degree of pushing back by the expanding HeLa-cell colonies and the strength of fibroblast proliferation.

6. Appearance of areas with abundant multinucleated HeLa cells. The frequency of multinucleated cells in HeLa cell monolayers was very low. Usually, 1-2 multinucleated cells were seen in a HeLa-cell colony with approximately 300 cells (Figure 17). However, in the co-cultures of HeLa and fibroblasts, areas with abundant multinucleated HeLa cells, always at the edges of the colonies, were frequently observed (Figure 27) (see also Figures 8, 9 in reference 186). Most of these cells contained nuclear abnormalities and micronuclei, indicating previous abnormal mitoses. Rarely, some of these multinucleated HeLa cells contained a nucleus of possibly fibroblast origin, as judged from the distinctly different colors of the nuclei of HeLa cells and those of fibroblasts when stained with Giemsa (Figure 28). Whether or not this was a result of cell fusion was not further investigated. Multinucleated HeLa cells soon became apoptotic with nuclear fragmentation and profound cytoplasmic membrane blebbing as described below (section 8; apoptosis) (Figures 63, 64).

7. Proliferation and metabolic activities in HeLa cell-fibroblast co-cultures. The following techniques and markers indicating proliferative and metabolic activities were applied in HeLa cells, fibroblasts and their co-cultures: Ki-67 proliferation antigen, NSE, E-cadherin, silver staining, DHFR and lipid staining.

7a. Ki-67. HeLa cells positively stained for Ki-67, with a high intensity in the nuclei, indicating cell proliferative capacity. HeLa-cell colonies staining for Ki-67 showed an increased activity in the foci of cells in central areas. The periphery of the HeLa colonies did not share the same increased activity, even in areas where two HeLa-cell colonies adjoined (Figure 29). Fibroblasts did not exhibit positive Ki-67 staining even in areas of dense growth. However, in co-culture with HeLa cells, fibroblasts induced intense Ki-67 staining in HeLa nuclei at the edges of the HeLa-cell colonies which were in contact with the dense encircling fibroblast areas (Figures 30, 31). The latter exhibited a pink cytoplasmic color (Figure 32), which became very intense after 10 days of co-culture, still without any staining of the nuclei (Figure 33).

7b. NSE live staining. HeLa cells expressed NSE activity, especially in the area surrounding the nucleus; however, when acetazolamide, an inhibitor of carbonic anhydrase (CA) was used, this activity almost disappeared. This shows that the activity in HeLa is attributed to CA and not to NSE. CA was amply expressed around the nucleus and in numerous cytoplasmic granules in both cell types (Figure 34), as shown utilizing the live cell staining technique described in the Materials and Methods section. The CA-granules in cytoplasmic projections of fibroblasts in contact with HeLa cells were markedly larger (Figure 35, live cell staining; Figure 36, paraformaldehyde-fixed cells). CA in co-culture was abundantly expressed, especially in the encircling fibroblast bows and the foci of HeLa cell piling up, with intense diffusion in paraformaldehyde-fixed preparations (Figure 36). However, when acetazolamide was used, the true NSE activity was revealed to be red only on the dense fibroblast areas surrounding the HeLa-cell colonies and the HeLa colony piling up in the centre seen with live-cell staining for $2^{1/2}$ h (Figures 37, 38). When staining was continued for 4 h, higher activity also appeared in HeLa cells (Figure 39). Staining of paraformaldehyde-fixed cells for NSE gave inferior results, with blurred appearance of the stained areas. Using live-cell NSE staining, NSE activity first appeared at 5 min on the nuclear membrane of the fibroblasts and then at 15 min in the cytoplasm as spherical stained droplets.

7c. Silver staining. Using silver staining, the cytoplasm of HeLa cells was stained light yellow and the nuclei dark brown with black nucleoli. Fibroblast nuclei were stained brown to dark brown with black nucleoli and the cytoplasm was stained brown (Figure 40). By monitoring the staining under the microscope, after the same duration of staining (about 30 s), HeLa cytoplasm was yellow, while that of fibroblasts was brown. Longer staining resulted in very dark uninterpretable staining.

From the fourth day of co-culture, progressively increasing argyrophilia (silver staining) (Figures 26, 41) and basophilia (Giemsa staining) (Figures 23, 24) were observed in the dense layer of fibroblasts surrounding the HeLa-cell colonies (Figure 41). Eventually, from the sixth day of co-culture, the fibroblasts developed an anarchic growth pattern, with overlapping cells and unusually long dark brown argyrophilic cytoplasmic projections (Figures 42, 43). These observations indicate that in the regions of dense growth, the fibroblasts underwent a further phenotypic change (after their dense growth), characterized by higher amounts of argyrophilic (basic) proteins and an intense tendency to elongate and overlap each other. Alongside this phenomenon, gaps started to appear in the periphery of the HeLa-cell colonies, clearly due to detachment of HeLa cells (Figure 43 a, b; described in Results Section 8).

Figure 29. *HeLa-cell colony boundaries do not show increased staining of Ki-67 even in areas where two HeLa-cell colonies adjoin. ×40.* Figures 30, 31, 32, 33. *Ki-67 activity in co-cultures of HeLa cells with LA-BC cells after 6 days (Figure 30, ×40), 8 days (Figure 31, ×40, Figure 32, ×100) and 10 days (Figure 33, ×100). Intense pink cytoplasmic staining of the fibroblasts after 10 days can be seen.* Figure 34. *Carbonic anhydrase expression (CA) in numerous cytoplasmic granules in both fibroblasts and HeLa cells. KR-BC fibroblasts and HeLa cells co-cultured for 11 days. Live staining. ×252.* Figure 35. *Intense CA expression (arrow) in fibroblast cytoplasmic projections in contact with HeLa cells. KR-BC fibroblasts and HeLa co-cultures for 11 days. Live staining. ×252.* Figure 36. *CA reaction in KR-BC fibroblasts and HeLa co-cultures for 11 days. Esterase staining of paraformaldehyde-fixed coverslips. Intense CA staining in both HeLa and fibroblasts is obvious. The arrow indicates intense expression in fibroblastic cytoplasmic projections in contact with HeLa cells. ×252.* Figure 37. *Non-specific esterase (NSE) staining of LA-BC fibroblasts and HeLa cells, co-cultured for 13 days, using acetazolamide (CA inhibitor) and the live staining technique. NSE activity is located in the areas of fibroblasts surrounding the HeLa-cell colonies as well as in the piling up at the centre of the HeLa colonies. Staining time: 2 1/2 h. ×30.* Figure 38. *As in Figure 37, live NSE staining with acetazolamide. Staining time: 2 1/2 h. ×10.* Figure 39. *As in Figure 37, live NSE staining with acetazolamide. Staining time: 4 h. Intense NSE activity can be seen in the areas of dense fibroblastic growth (arrows). ×25.* Figure 40. *Silver staining of a monolayer of KR-BC cells. ×120.*

Figure 41. *Composite image of a KR-BC fibroblasts and HeLa cell co-culture. An inoculum of 10^5 KR-BC cells in 1 mL medium was cast over a monolayer of HeLa-cell colonies (with ~10-40 cells) and cultured for 10 days, with medium replacement every 2 days. A polygonal pattern of co-growth, dense growth of fibroblasts around HeLa cells and gaps along the boundaries of the HeLa colonies are clearly visible. Silver staining. ×50.*

Figure 42. *a: Anarchic pattern of growth of KR-BC fibroblasts surrounding HeLa-cell colonies after 10 days of co-culture. b: High magnification (x200) of the left inset in part (a) (x20), showing a fibroblast with long argyrophilic projections. c: High magnification (x240) of the right inset in part (a), showing anarchic growth of fibroblasts with overlapping cells and intense argyrophilia. Silver staining.* Figure 43. *a: HeLa colonies surrounded by densely grown highly argyrophilic fibroblasts (×60), b: Detail of the inset indicated in part (a) showing the development of complex long cytoplasmic argyrophilic projections of fibroblasts and gaps along the boundaries of the HeLa-cell colony (×270). KR-BC fibroblasts and HeLa cells, 12 days of co-culture, Silver staining.*

7d. E-Cadherin. Neither HeLa cells nor fibroblasts expressed E-cadherin when cultured alone. Nevertheless, in co-culture for 11 or 14 days, E-cadherin appeared to be profoundly expressed at the peripheries of HeLa colonies surrounded by fibroblasts (Figure 44 a, b). Expression of E-cadherin was visible around parts of the HeLa cell nuclei, with some diffuse positivity in the cytoplasm, and rarely, in the nucleus (Figure 44c). In multinucleated HeLa cells, only a small part of the cytoplasm was E-cadherin-immunopositive, whereas the nuclei were negative.

7e. DHFR. Although the boundaries of HeLa-cell colonies when alone did not stain intensely for DHFR (Figure 45), when such colonies were surrounded by fibroblasts, a very intense DHFR reaction was observed occupying a wide zone of about 5-12 HeLa cells from the point of contact with the fibroblasts towards the centre of the colonies (Figures 46, 47, 48).

The appearance of a very remarkable increase of strongly luminous mitotic cells within this zone indicated growth stimulation. HeLa cell nuclei stained dark blue, nucleoli darker blue and cytoplasm light blue. The cytoplasm and nuclei of the fibroblasts stained very faintly for DHFR (Figure 49), while some staining of nucleoli was seen at high magnification. Rarely, some cells of fibroblastic morphology around the HeLa-cell colonies showed intense cytoplasmic and nuclear DHFR staining, which may indicate that these cells were starting to enter the mitotic phase.

7f. Live staining of lipid. From the sixth day of co-culture, a progressive increase in the production and secretion of high numbers of lipid droplets by the encircling dense layer of fibroblasts was noticed (Figures 50, 51). These droplets accumulated only over the fibroblasts surrounding the HeLa-cell colonies and could be easily dislodged by agitation or moderate medium flow over them. When using methanol- or paraformaldehyde-fixed cell monolayers, these droplets dissolved and were not seen in fixed cells. In fixed HeLa cells, lipid staining was located in granules around the nuclei (Figure 52), while in fibroblasts it was located in cytoplasmic granules (Figure 53).

Figure 44. *HeLa colonies surrounded by KR-BC fibroblasts after co-culture for 11 days, stained for E-cadherin. a: negative control (x50). b: E-cadherin expression located at the HeLa colony periphery (x50).*

In co-culture, both cell types but even more so the fibroblasts, had higher numbers of lipid-stained cytoplasmic granules (Figure 54 a, b). In the dense layer of fibroblasts, lipid staining was diffuse (Figure 54 a, arrow) because of large lipid droplets that were loosely attached to the fibroblasts (Figure 51).

8. Apoptosis in HeLa-fibroblast co-cultures. Four distinctive phenomena were observed with increasing frequency after nine to ten days of co-culture close to the boundaries of HeLa-cell colonies surrounded by densely growing fibroblasts:

(a) detachment from the glass surface of groups of HeLa cells (Figures 43 a, b, 55, 56, 57, 58); (b) dilution of the HeLa cell density due to detachment after cell death and cytoplasmic shrinkage (Figures 32, 33, 41, 43, 57, 58); (c) areas of very dense growth of fibroblasts (close to HeLa-cell colony edges), with long, highly argyrophilic cytoplasmic projections and cell overlapping (Figures 42, 43, 55, 56); (d) regrowth of HeLa cells in areas of detachment but also within fibroblastic territories (Figures 57, 59, 60).

Small cytoplasmic fragments, mostly containing a darkly-stained small nucleus, were frequently observed from day 10 and were abundant after day 15 in areas of reduced HeLa cell density where, however, the fibroblasts did not show signs of distortion (Figures 61 a, b, 62 a, b, c; also Figure 56 upper part).

From the tenth day of co-culture, a continuously increasing occurrence of apoptotic features in HeLa cells was observed including nuclear fragmentation, cell shrinkage and long, thin projections (condensed basophilic cytoplasm), chromatin condensation, micronuclei, nuclear abnormalities, membrane-bound apoptotic bodies (small cells), and cellular membrane blebbing (Figures 62, 63, 64, 65). Cell fragments with similar features (fragmented nuclei, dark condensed cytoplasm and blebbing) were also observed during the first and second passages of fibroblasts isolated from human breast tumours (Figures 3 a, b, 4), most probably originating from apoptotic cancer cells.

Nuclear abnormalities were rarely observed in fibroblasts. These included nuclear fragmentation, nuclear gaps, nuclear membrane indentations and multinucleated cells (Figure 66 a, b, c, d, e).

Cytotoxic effects on HeLa cells were exhibited by all the finite fibroblastic cell lines used (Table I) and were not differentiated by fibroblast origin.

After 17 days, control HeLa-cell colonies covered the whole coverslip, piling up very extensively, and started to detach in batches, mainly at the colony centre, and did not have multinucleated cells, apoptotic features, regrowth or sparse growth. The pattern of HeLa cell detachment at the piled-up centre of HeLa colonies (*e.g.* Figure 26) was completely different from the detachment of HeLa cell groups from the HeLa-colony boundaries during their interaction with fibroblasts (Figure 41).

9. Blockade of fibroblasts at G_2-M phase after 17 days of HeLa cell–fibroblast co-culture. After 17 days of co-culture of HeLa cells (colonies) with fibroblasts, extensive areas of the co-culture contained a high proportion of fibroblasts blocked in early to late (G_2-M) prophase (Figure 67 a, b) as shown by fading and disappearance of the nucleolus, disappearance of the nuclear membrane and by chromatin condensation into chromosomal regions (Figure 68 a-e). G_2-M nuclei were usually ovoid or exceptionally elongated (Figure 69 a-d), usually with a constriction (Figure 69 arrows). These observations show that the effects of HeLa cell–fibroblast interactions extend to alterations of the chromatin organization in fibroblasts.

Figure 44c. *E-Cadherin expression in HeLa cells in co-culture with KR-BC cells for 11 days. Conditions were as described in the legend to Figure 23. ×500.* Figure 45. *Part of a control HeLa-cell colony stained for DHFR. Cells which have just divided are brightly stained (centre). ×100.* Figure 46. *HeLa-cell colonies surrounded by fibroblasts exhibit very intense DHFR staining perimetrically and in a wide zone of boundary HeLa cells. LA-BC fibroblasts and HeLa cells co-cultured for 9 days. Conditions were as described in the legend to Figure 23. ×60.* Figure 47. *b: Same as shown in legend to Figure 46. DHFR-staining with light 1-min Giemsa counterstaining. ×50.* Figure 48. *Gaps (arrow) along the boundaries of the HeLa-cell colonies in areas of anarchic fibroblast growth. LA-BC fibroblasts and HeLa cells cultured for 9 days. Conditions were as described in Figure 23. DHFR staining with light 1-min Giemsa counterstaining. ×80.* Figure 49. *LA-BC fibroblast monolayer stained for DHFR. ×30.* Figure 50. *Accumulation of lipid droplets over dense layers of fibroblasts surrounding HeLa-cell colonies. KR-BC fibroblasts and HeLa cells were co-cultured for 10 days. KR-BC cells (10^5 in 1 mL medium) were cast over a monolayer of sparse HeLa-cell colonies (6-10 cells/colony) on a 1×1 cm coverslip and co-cultured for 10 days with medium replacement every 2 days. Sudan Black staining. ×10.* Figure 51. *High magnification (from Figure 50) of the lipid droplets accumulated over the surrounding fibroblasts. By adjusting the focus, large homogeneously light-staining droplets were seen located over the fibroblasts (arrow). Fibroblasts carried small darkly-stained lipid cytoplasmic granules, which can also be seen here (double arrow). ×300.* Figure 52. *Lipid staining in HeLa cells was located in granules around the nuclei. Sudan Black staining. ×300.* Figure 53. *Lipid staining of cytoplasmic granules in KR-BC fibroblasts. Sudan Black staining, ×50. Similar lipid staining was obtained for all SF cell lines used.* Figure 54. *Lipid staining in KR-BC fibroblasts and HeLa cells co-cultured for 10 days. In the dense fibroblastic areas (arrow in part a), the large lipid droplets caused diffused staining (see part b), while in less dense areas of fibroblasts (asterisk) as well as in areas colonized by HeLa cells (double arrow), cytoplasmic lipid granules are obvious. Sudan Black staining. a: ×30; b: box from Figure 54a, ×80.*

Figure 55. *Detachment from the glass surface of groups of HeLa cells from the peripheries of HeLa-cell colonies surrounded by densely growing highly argyrophilic fibroblasts. KR-BC and HeLa cells cultured for 10 days. Conditions were as described in the legend to Figure 50. Silver staining a: ×60; b: ×120. Figure 56. Higher magnification of the inset in Figure 54 b. ×600. Figure 57. As in Figure 55, after 12 days of co-culture. Larger empty areas of detached HeLa cells but also resurgence and growth of HeLa cells outside the dense surrounding fibroblast layer can be seen (arrow). Silver staining, ×30. Figure 58. As in Figure 55, after 12 days of co-culture showing extensive HeLa cell detachment. Silver staining, ×30.*

Figure 59. *As in Figure 55, after 10 days of co-culture, showing area of HeLa cell detachment, with some HeLa cells attached on the inner side of the surrounding stromal fibroblasts (arrow). DHFR staining with 1-min Giemsa counterstaining. ×50.* Figure 60. *As in Figure 55, after 12 days of co-culture, showing complete detachment of a small HeLa-cell colony, resurgence of two new HeLa colonies (single arrows) and regrowth of some HeLa cells on the side of the surrounding fibroblasts (double arrow). KR-BC fibroblasts and HeLa, DHFR staining with 1-min Giemsa counterstaining. ×140.*

10. Transfer of small molecules between HeLa cells and fibroblasts in co-culture. Transfer of ^{3}H-TdR from pre-labeled HeLa cells or fibroblasts to non-labeled fibroblasts or HeLa cells, respectively, was never observed in any cell ratio. Autoradiography of co-culture coverslips after 3 h to 20 days revealed that ^{3}H-labeled grains remained only on the nuclei of the pre-labeled cells (Figure 70 a, b). None of the fibroblastic lines used differed in their pattern of interaction.

Transfer of ^{3}H-UdR from fibroblasts to co-adhered HeLa cells, and through them also to HeLa cells that were not co-adhered to fibroblasts, occurred rapidly, at as early as 1 h or less of co-culture, until the density of ^{3}H-labeled grains in the HeLa cells reached almost the same as that in the fibroblasts (after 10 h) (Figure 71 a, b).

However, transfer of ^{3}H-UdR from HeLa cells to co-adhered fibroblasts occurred at a lower rate and the number of ^{3}H-labeled grains over the fibroblasts reached only 1/10 that over HeLa cells after 10 h (Figure 72).

Similar autoradiography results were obtained with G-EP, SE-L, PG-BC and TONS-F cells.

11. The HeLa–fibroblast co-culture battlefield after 17 days. After 17 and up to 20 days (Figures 73-75), the co-cultures presented the following features: (a) extensive areas of very dense growth of fibroblasts with a complex network of long highly argyrophilic projections and foci of overlapping and piling up cells. This feature started to appear from the ninth day of co-culture (Figures 43, 55, 56, 75); (b) areas with both fibroblasts and HeLa cells with a sparse pattern of growth including small colonies of HeLa cells, several abnormal or apoptotic HeLa cells, and rarely, fibroblasts with nuclear abnormalities (Figures 62, 66, 73, 74); (c) areas with a high percentage of fibroblasts blocked at the G_2-M phase of the cell cycle (Figure 67); (d) foci with unusually high numbers of multinucleated HeLa cells with apoptotic features (Figures 63, 64, 65); (e) areas with extensive disintegration of HeLa cells (Figures 62, 75); (f) areas of destroyed HeLa-cell colonies showing extensive detachment of HeLa cells, but also their regrowth in the same areas attached to surrounding fibroblasts (Figures 57, 58, 59, 60) or forming dense colonies (Figure 60).

These observations show that under biomechanical forces, communication and interactions, fibroblasts and HeLa cells influence each other's growth pattern and survival. These developments do not occur in clearly separated steps, since foci of all the above features co-existed after 17-20 days of co-culture, with some of them appearing as early as nine days after the start of co-culture.

The duration of time that the two cell types are in contact seems to topologically influence the emanation and sequence of specific events, which also depends on frequent replacement of medium.

Subculture of the co-cultures after the 17- to 20-day period produced either a mixture of the two cell types or a HeLa cell or fibroblast monolayer with contamination with the other cell type, or, rarely, only fibroblast cells. Some of the fibroblastic cell lines used (G-EP, AK, PL-BC) were able to completely destroy HeLa cells when the initial ratio of HeLa cells:fibroblasts was very low (<1:100); however, this phenomenon was not apparent for all the finite fibroblastic cell lines used. No association of this phenomenon with a specific origin of fibroblasts was

Figure 61. *As in Figure 55, after 10 days of co-culture showing detachment of HeLa cell groups (a), (b): magnification of the inset in Figure 61a showing a large area with many mini-cell fragments originating from HeLa fragmentation. These mini-cell fragments became more abundant after the 15th day of co-culture. KR-BC fibroblasts and HeLa, Silver staining, a: ×60; b: ×180. Figure 62. As in Figure 61 b, after 15 days of co-culture showing abundance of mini-cell fragments, intact fibroblasts and some reviving HeLa cells. Giemsa. a: G-EP fibroblasts and HeLa , ×320, b: ×320, c: KR-BC fibroblasts and HeLa, ×50. Figure 63. Apoptotic features of multinucleated HeLa cells after 15 days of co-culture with LA-BC cells. Conditions were as described in Figure 50. Giemsa, ×800.*

Figure 64. *Apoptotic features of HeLa cells after 15 days of co-culture with LA-BC fibroblasts. Nuclear fragmentation and intense cytoplasmic blebbing are apparent. Giemsa. a: ×120; b: higher magnification of the inset in a; ×252.*

established. It should be noted, however, that all fibroblasts used were capable of inducing apoptosis and detachment of HeLa cells. Moreover, all of them produced lipid droplets when they were densely growing around HeLa-cell colonies.

Discussion

The interactions between malignant epithelial cells and the tumour microenvironment, including stromal fibroblasts, for solid tumours involve growth interdependence and abnormal growth control mechanisms, that advance tumourigenesis to invasion and metastasis (270, 271). It is generally held that carcinogenesis is the result of a series of initial genetic alterations in a target cell, which then causes modulations of the developing nearby tissue environment, thus facilitating the un-interruptive growth of a tumour (1, 3). Therefore, the existence of a tumour presupposes that abnormal cancer cells have surpassed the immune system's homeostatic mechanisms and have established a modified cancer-supportive microenvironment. Obviously, if the initial effort of a small colony of cancer cells fails to overcome the immune surveillance and to create an efficiently supportive microenvironment, the tumour will not develop (251). Therefore, there is a critical point at which a tumour will start developing, or succumb under the restraint of its microenvironment (6-8, 11, 46, 186, 251). The role of fibroblasts at this point is unclear since most relevant studies examined fibroblasts after the establishment of a fully-grown tumour. Such studies have shown that CAFs may be supportive or suppressive of tumour growth and progression to invasion and metastasis, as described in the Introduction.

However, the initial stages before the crucial point of overcoming the immune surveillance mentioned above have not been investigated. The present study constitutes a detailed description of the early interactions between proliferating fibroblastic cells of different origins with HeLa cells, based on a previously developed *in vitro* model (6, 9, 119, 186).

Stromal fibroblasts comprise a highly heterogeneic entity within the tumour microenvironment. Our previous studies showed that SFs isolated from human breast tumours may exhibit an intense tendency *in vitro* for overlapping growth, with loss of parallel cell growth and loss of contact inhibition (134, 142) (Figure 2). This property is also seen in normal skin fibroblasts, but only if they are co-cultured under certain conditions with HeLa cells (*e.g.* Figure 23). The present experiments showed that both normal skin- and tumour-derived fibroblasts change their characteristic properties stepwise during their cell–cell interactions with HeLa cells. An adaptable character for fibroblasts, compatible with the meaning of cell plasticity (92, 157, 272, 273), entailing reprogramming of their gene expression, protein synthesis and function, is thus also revealed in the present cell-interaction model.

Differences between normal fibroblasts and CAFs regarding proliferation, contact inhibition of growth, gene expression and phenotypic profiles have been reported in many studies (9, 43, 53, 135, 168, 274, 275). Stromal fibroblasts ultimately acquire versatile properties that may be supportive, inhibitory or definitively destructive for cancer cells and their metastatic capacity (6-9, 46, 65, 80, 82, 92, 170, 186, 206, 213, 227, 251, 273, 276). Studies of *in vitro* interactions between isolated fibroblasts and cancer cells may therefore provide information on and explanations for their

Figure 65. *Apoptotic HeLa cells after 18 days of co-culture with LA-BC fibroblasts. Cytoplasmic blebbing and bi-nucleate cells are visible. Conditions were as described in Figure 50. Giemsa, ×140. Figure 66. Nuclear abnormalities of various fibroblasts co-cultured with HeLa cells revealed by Giemsa staining. a: A nuclear constriction (arrow) frequently observed in all the stromal cell lines used. KA-BC fibroblasts and HeLa cells, ×1000. b: Abnormal nuclear shape of a KA-BC cell after 6 days of co-culture with HeLa cells, ×1000. c: Fragmented nucleus of a TONS-F cell observed during the attachment of a HeLa cell, ×500. d: Nuclear fragmentation of an LA-BC cell (arrow) observed after 15 days of co-culture with HeLa cells, ×100. e: Multinucleated TONS-F cell (arrow) after 15 days of co-culture with HeLa cells. ×120. Figure 67. a: Blockade of KR-BC fibroblasts in early-to-late prophase (G_2-M) after 18 days of co-culture with HeLa cells. Giemsa, ×120. b: Higher magnification of the inset in Figure 67a: top right: HeLa metaphase with chromosome non-disjunction; centre: two small HeLa cell fragments, left: multinucleated HeLa cell with abnormal nuclei; Four G_2-M fibroblast nuclei. ×240.*

Figure 68. *Early-to-late (G_2-M) prophase nuclei of fibroblasts (KR-BC) after 18 days of co-culture with HeLa cells. Giemsa. a: Nucleus at early S-G_2 phase ×2000; b: early prophase nucleus with obvious nucleoli ×1000; c: early prophase nucleus with nucleoli starting to fade ×2000; d: disappearance of nucleoli ×2000; e: disappearance of nuclear membrane and clear appearance of nuclear chromosomal territories ×2000.* Figure 69. *G_2-M nuclei were ovoid (a, b) or exceptionally elongated, usually with a characteristic constriction (arrow) Giemsa, a, c: KR-BC fibroblasts and HeLa cells; b, d: LA-BC fibroblasts and HeLa cells. a: ×500, b: ×1000; c: ×500; d: ×1500.*

behaviour and function in the complex *in vivo* situation. The present results show that fibroblasts from various origins share common properties during the different stages of their interactions with cancer cells.

Confluent fibroblasts, which cease to divide, are supportive of cancer cell growth and are characterized as feeder layers, usually pre-irradiated (277). Fibroblasts also cease to divide if nutrient medium is not regularly renewed. Thus, the aim of studying the *in vitro* interactions between cancer cells and proliferating fibroblasts was justified and furthermore

supported by the fact that desmoplasia, as a characteristic feature of most tumours, actually consists of early-initiated fibroblast growth within the tumour microenvironment (9, 46, 51-55, 64, 79, 162, 278).

From the initial stages of their *in vitro* interactions, the intense affinity between cancer cells and fibroblasts clearly creates a topologically heterogeneous environment on the glass culture surface, giving rise to the question whether fibroblasts in contact with cancer cells acquire properties different from those of fibroblasts growing or wandering far

Figure 70. *Autoradiography of a co-culture of HeLa cells with ³H-TdR-pre-labeled G-EP fibroblasts. ³H-TdR-G-EP (10³ cells in 1 mL medium) were cast over a monolayer of small (6-40 cells) HeLa-cell colonies and cultured for 15 h (a). There is no transfer of grains from the fibroblasts to HeLa cells. Identical results were also obtained if 10³ HeLa cells were mixed with ³H-TdR-labeled fibroblasts before plating and cultured for 15 h (b) or 15 days. Same results were obtained with AK, PG-M, SE-L, TONS-F and PL-BC cells. a: x500, b: ×240. Figure 71. Autoradiography of a co-culture of HeLa cells with ³H-UdR-pre-labeled G-EP fibroblasts. ³H-UdR-G-EP (10³ cells in 1 mL medium) were cast over a monolayer of small (6-40 cells) HeLa-cell colonies and cultured for 10 h (a). Extensive transfer of grains from a heavily labeled fibroblast to all the cells of the HeLa-cell colony can be seen. ×200. The same phenomenon was observed when HeLa cells were cast over a monolayer of ³H-UdR-pre-labeled G-EP fibroblasts and cultured for 10 days (b: ×200). Figure 72. Autoradiography of a co-culture of ³H-UdR-pre-labeled HeLa cells with SE-L fibroblasts. HeLa cells (10³ cells in 1 mL medium) were cast over a non-confluent monolayer of SE-L fibroblasts and cultured for 10 h. A HeLa cell has attached to the side of a fibroblast and grains have already been transferred to the fibroblast, with a higher accumulation in the nucleoli. ×200.*

away. There is evidence that stromal cells adjacent to tumours, stroma close to tumours, and stroma more than 15 mm from tumours display differentially-expressed genes (279) and histological heterogeneity (71, 72). Additionally, various other types of heterogeneity have been described (9, 43, 65, 82, 133, 135). Indeed, in our *in vitro* experiments, both cell types first contacted side by side and then showed intense proliferation and various changes in their protein expression profile, dependent on their topology. This phenomenon, involving active fibroblast locomotion, proliferation, cell adhesion and contact guidance, is reminiscent of biomechanical morphogenetic processes during embryogenesis and organ formation (146, 147, 280). Furthermore, it shows that the fibroblasts acquire functions which are specific to their position. As can be seen from Figures 11, 12, 13, 23, 24, 42, 61 and 64, in the course of their interactions with HeLa cells, fibroblasts first circumscribe HeLa-cell colonies, then actively proliferate and finally cause the appearance of apoptotic foci, specifically at the boundaries of HeLa-cell colonies. Thus, the present results indicate the development of a restraining role of the fibroblasts in cancer progression. The affinity of the fibroblasts for HeLa cells may be interpreted as an indigenous property of all kinds of mesenchymal cells to provide a supportive background for epithelial cells. On the other hand, the intense proliferation of the HeLa cells located at the outer edge of the colonies may indicate a feeding relationship (119) or competition for nutrients (281). Indeed, in our model, it was shown that the growth of HeLa cells at the periphery of colonies is enhanced if the colonies are surrounded by proliferating fibroblasts. This was shown by the expression of Ki-67 proliferation antigen and of DHFR, an enzyme associated with the *de novo* synthesis of amino acids and nucleic acid bases in the S phase of the cell cycle (282, 283). However, this friendly cooperation is reversed only a few generations later, as evidenced by extensive disintegration characteristics at the edges of the HeLa-cell colonies (Figures 48, 55, 56, 57, 58, 61). This phenomenon may indicate the capacity of certain fibroblasts to recognize the malignant cells and to cause their destruction by apoptosis or mitotic catastrophe (284) (Figures 43, 48, 55, 61, 62, 63, 64). Despite, however, this aggressive effect exerted by the fibroblasts, the HeLa cells managed to grow again and started forming new colonies (Figures 57, 60, 62, 75).

Figure 73. *KR-BC fibroblasts and HeLa cell co-culture. An inoculum of 10⁵ KR-BC cells in 1 mL medium was cast over a monolayer of HeLa-cell colonies (with 6-10 cells) and incubated for 17 days, with medium replacement every 2 days. Dense growth of the fibroblasts, with long projections and overlapping cells, foci of apoptotic HeLa cells, mini-cell fragments, revival of HeLa cell growth and maintenance of some semblance of the polygonal pattern of cogrowth is apparent. Giemsa, ×40.* Figure 74. *As in Figure 73, co-culture of KR-BC fibroblasts and HeLa cells for 18 days. The expansion of the fibroblast growth in the space previously occupied by HeLa colonies is obvious. Giemsa, ×40.* Figure 75. *Higher magnification of the inset in Figure 74. Giemsa, ×180.*

The contact between fibroblasts and HeLa cells, in the present study, was shown to be necessary for activating the process of protein expression changes in both cell types. Obviously, the overproduction of a specific protein (*e.g.* NSE, DHFR, E-cadherin) should require the overexpression not only of the specific gene but also of the series of genes involved in the provision of all necessary elements for the synthesis of that specific protein. Thus, such 'activated' cells should be expected to exhibit increased metabolic and transcriptional activity (285) and intense protein synthesis, being evident by their intense cytoplasmic basophilia and argyrophilia (Figures 42, 43, 55, 56). Cytoplasmic silver staining in these interaction experiments reflects an increased transcriptional activity for proliferative and functional needs of the cells (286, 287). Silver staining was sensitive in detecting material that could not be demonstrated by Giemsa, *e.g.* the long strongly argyrophilic fibroblastic projections. Nevertheless, basophilic and argyrophilic cytoplasm, as shown by Giemsa and silver

staining, respectively, means that the cell is actively producing proteins. It should be mentioned that numerous proteins associated with many fibroblastic functions are argyrophilic (such as fibronectin type III, collagen, and ribosomal proteins). Additionally, protein synthesis in the fibroblasts may be assisted by frequent replacement of the medium and through direct cell-cell communicative exchanges of large and small molecules with HeLa cells (80, 119, 288-290). Moreover, this process may assist in the synthesis of specific proteins. The fast transportation of free ^{3}H-UdR from fibroblasts to HeLa cells shows active metabolic cooperation between the two cell types for RNA synthesis. The contribution of the frequent replacement of the medium to the process of alteration of protein expression in the fibroblasts is evident since interruption of nutrient supply results in fibroblasts changing to a non-proliferating state where they are used just as a feeder layer by HeLa cells (Figures 5, 6, 7). Consequently, these fibroblasts, *i.e.* CAFs, that may or may not express α-SMA (291), can only serve as fodders for the cancer cells. It is interesting to note that suppression of α-SMA in stromal cells resulted in suppression of breast cancer metastasis *in vivo* (292). The feeding role of CAFs may also be supported by their properties, to express mainly genes of structural proteins (25, 29, 68, 86, 87, 129, 293), to be located in areas of cancer-cell proliferation such as the invasion front (53, 82) and to preselect and prepare a tissue to accept metastatic cancer cells (169, 270, 276, 294).

All these observations are compatible with the supportive nature of CAFs, however, they do not exclude or diminish the notion of stromal fibroblasts potentially becoming aggressive against cancer cells, opposing or destroying them. There are indeed numerous examples of such a spectrum of effects of fibroblasts against cancer cells, both *in vitro* and *in vivo*, as described in the Introduction. On the other hand, the tumour microenvironment is a region of ambiguous, positive and negative responses to various factors *e.g*. IL-6 (295).

The expression of E-cadherin in the periphery of HeLa cell colonies surrounded by fibroblasts for 11 days or longer in this study (Figure 44) suggests a direct regulation of E-cadherin by the fibroblast interaction. This may indicate alterations of epithelial barrier permeability and cellular-junction properties, as previously shown by the modulation of the expression of E-cadherin in cancer cells by fibroblasts in several co-culture systems (296-300). E-Cadherin is not expressed in several types of tumours but its expression may be associated with suppression of tumour growth (301). The involvement of E-Cadherin in tumourigenesis, metastasis and tumour suppression is a complex phenomenon, varying among different cell types and tissues (302-304). Remarkably, remodeling of stromal-specific proteins and E-cadherin expression in the epithelioid cells of benign prostate hyperplasia has been shown to facilitate the transfer of epithelial-secreted proteins to the stroma (305).

The production and release of lipid droplets by the dense fibroblast layers surrounding the HeLa-cell colonies is a novel finding. Although the function of lipids in cancer remains unclear, they evidently play a significant role in cancer progression (306, 307). Adipogenesis is related to fibrosis, and the interconversion between stromal fibroblasts and adipocytes is involved in carcinogenesis (308, 309). Furthermore, adipocytes contribute to breast cancer invasion (310). From our experiments, it may be suggested that, during their close interaction with HeLa-cells, fibroblasts produce lipids in their cytoplasm that are finally released and accumulate on their upper cell surface (Figures 50, 51, 54).

The apoptotic features observed at the border of HeLa-cell colonies after ~10 days in co-culture with fibroblasts clearly constitute an effect of the bidirectional communication and interactions between the two cell types in contact since conditioned medium did not induce these cytotoxic effects (6, 119, 186). The presence of foci with many multinucleated HeLa cells possibly indicates that in these particular areas, close to the edge of HeLa colonies, as well as to the dense fibroblast bow, specific factors affect the process of mitosis leading to incomplete telophase without cytoplasmic division. This view is supported by the high frequency of nuclear abnormalities observed in HeLa cells in the present study, and also by the nuclear atypia in cancer cells surrounded by CAFs (311).

NSE consists of a large group of hydrolytic enzymes with variable staining intensity in different cells and tissues (312). They may present peculiarities in staining due to their sensitivity to pH, osmolarity and fixation method (313, 314). NSE is localized in the cytoplasm, with diffuse staining, or in lysosomes, with spherical droplet staining (313, 315). Since carbonic anhydrase (CA), an enzyme ubiquitously-expressed in almost all cells (265, 316, 317), is abundantly stained with the NSE reaction used, it was necessary to use acetazolamide, a specific inhibitor of CA, so that true NSE expression could be revealed (263, 264, 314). NSE was used as a general marker to show that most probably a very wide range of proteins are produced by the encircling fibroblasts during their interactions with HeLa cells, as also shown by the intense silver staining. It should be noted that CA and specific esterases have been suggested to play a role in cancer progression (316-318).

The blockade of the fibroblasts at the G_2-M phase of the cell cycle, after only 17 days in co-culture with HeLa cells, shows a time-dependent effect on the nuclear membrane, nucleolus and chromatin organization of the fibroblasts. The importance of the observation of such nuclear features has been stressed for cancer cells (319-321), but never before for fibroblasts following their interaction with cancer cells *in vitro* or *in vivo*. The separation of the chromosomes in nuclear regions relates to gene expression and gene expression changes in transcriptional activity (319, 322). The possible

involvement of TGF-β signaling in this phenomenon (323), leading to alterations within the tumour microenvironment, should be further investigated.

The above discussion points to an indigenous common property of fibroblasts: namely a remarkable adaptability through the selective expression of certain proteins, thus facilitating specific functions under certain environmental conditions or under the influence of specific signaling. This is well-supported by many studies (45, 102, 105, 117, 324-329). Therefore, it could be postulated that the tumour fibrovascular stroma consists of many heterogeneous subpopulations of fibroblasts at different stages of proliferation and with a wide spectrum of alterations in protein expression (329, 330), whatever their designation is considered to be (CAFs, TAFs, myofibroblasts, mesenchymal stromal cells, mesenchymal stem cells, stromal fibroblasts, etc.). The phenomenon of the epithelial–mesenchymal transition and the involvement of other cell types were not included in this discussion.

Considering their strong affinity for cancer cells (119, 331, 332), as well as their various functions within the tumour microenvironment, mesenchymal cells have recently emerged as potential therapeutic targets or means against cancer (77, 104, 113, 153, 222, 333-342).

Enriching our knowledge on the *in vitro* and *in vivo* interactions of cancer cells with other tumour micro-environment cellular elements, and using new methodologies, such as delicate 3D culture (147, 249, 343-346), will be particularly useful for a more accurate simulation of the *in vivo* situation, allowing the mechanisms of specific interactions to be elucidated.

Conclusion

The protein-expression patterns of both fibroblasts and HeLa cells in *in vitro* co-culture depend on the topology, cell-to-cell contact, cell-to-cell ratio, duration of their interaction and avoidance of disruption of proliferating capacity of the fibroblasts due to contact inhibition or nutrient deprivation. Interactions of the two cell types gradually lead to changes in their growth and survival patterns. Fibroblasts develop a remarkable pattern of overgrowth around HeLa-cell colonies, express NSE, show intense silver staining and development of a complex network of long highly basophilic-argyrophilic projections, and produce lipids. At this stage, the signs of overgrowth of HeLa cells at the boundaries of HeLa-cell colonies give way to signs of apoptosis with gradually increasing detachment of HeLa cell groups.

It is certain that the co-culture of fibroblasts and HeLa cells *in vitro* produce a series of interactions, starting with acquaintance and mutual affinity, continuing with communication and effects on each other's protein expression and ending with a fight for survival. The important prerequisite for these observations is the enabling of fibroblast proliferation.

The present results justify an in-depth investigation of the conditions under which the flexible and industrious nature of fibroblasts can be manipulated in such a way that these cells can be utilized against cancer cells *in vivo*.

References

1   Stratton MR: Exploring the genomes of cancer cells: Progress and promise. Science *331*: 1553-1558, 2011.

2   Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science *331*: 1565-1570, 2011.

3   Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell *144*: 646-674, 2011.

4   Smithers DW: An attack on cytologism. Lancet 1: 493-499, 1962.

5   Rubin H: Cancer as a dynamic developmental disorder. Cancer Res *45*: 2935-2942, 1985.

6   Delinassios JG: Fibroblasts against cancer cells *in vitro*. Anticancer Res *7*: 1005-1010, 1987.

7   Witz IP: Tumour-Microenvironment interactions: Dangerous liaisons. Adv Cancer Res *100*: 203-229, 2008.

8   Witz IP: The tumour microenvironment: The making of a paradigm. Cancer Microenviron *2(Suppl 1)*: 9-17, 2009.

9   Angeli F, Koumakis G, Chen MC, Kumar S and Delinassios JD: Role of stromal fibroblasts in cancer: Promoting or impeding? Tumour Biol *30*: 109-120, 2009.

10 Räsänen K and Vaheri A: Activation of fibroblasts in cancer stroma. Exp Cell Res *316*: 2713-2722, 2010.

11 Eikesdal HP, Kalluri R: The multifaceted role of cancer associated fibroblasts in tumour progression. The Tumour Microenvironment *4*: 361-380, 2011.

12 Klopp AH, Gupta A, Spaeth E, Andreeff M and Marini F III: Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumour growth? Stem Cells *29*: 11-19, 2011.

13 Liao D, Luo Y, Markowitz D, Xiang R and Reisfeld RA: Cancer associated fibroblasts promote tumour growth and metastasis by modulating the tumour immune micro-environment in a 4T1 murine breast cancer model. PLoS One *4*: e7965, 2009.

14 Castelló-Cros R and Cukierman E: Stromagenesis during tumourigenesis: characterization of tumour-associated fibroblasts and stroma-derived 3D matrices. Methods Mol Biol *522*: 275-305, 2009.

15 Shimoda M, Mellody KT and Orimo A: Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol *21*: 19-25, 2010.

16 Mehner C and Radisky DC: Triggering the landslide: The tumour-promotional effects of myofibroblasts. Exp Cell Res *319*: 1657-1662, 2013.

17 Valastyan S and Weinberg RA: Tumour metastasis: molecular insights and evolving paradigms. Cell *47*: 275-292, 2011.

18 Khamis ZI, Sahab ZJ and Sang QX: Active roles of tumour stroma in breast cancer metastasis. Int J Breast Cancer 574025, 2012.

19 Maman S and Witz IP: The Metastatic Microenvironment. In: The Tumour Immunoenvironment. Edited by Shurin MR, Umansky V, Malyguine A, pp. 15-38, 2013, Springer Science+Business Media Dordrecht.

20 Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G and Sahai E: Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 15: 637-646, 2013.

21 Depner S, Lederle W, Gutschalk C, Linde N, Zajonz A and Mueller MM: Cell type specific interleukin-6 induced responses in tumour keratinocytes and stromal fibroblasts are essential for invasive growth. Int J Cancer 135: 551-562, 2014.

22 Bauer M, Su G, Casper C, He R, Rehrauer W and Friedl A: Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene 29: 1732-1740, 2010.

23 Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, Save V, Novelli M, Balkwill F and Fitzgerald RC: Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci USA 107: 2177-2182, 2010.

24 Wang J, Ying G, Wang J, Jung Y, Lu J, Zhu J, Pienta KJ and Taichman RS: Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumour micro-environment in prostate cancer progression. Cancer Res 70: 471-480, 2010.

25 Arendt LM, Rudnick JA, Keller PJ and Kuperwasser C: Stroma in breast development and disease. Semin Cell Dev Biol 21: 11-18, 2010.

26 Blanco MA and Kang Y: Signaling pathways in breast cancer metastasis – novel insights from functional genomics. Breast Cancer Res 13: 206, 2011.

27 Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RS 2nd, Revelo MP, Bhowmick NA and Hayward SW: Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res 71: 1272-1281, 2011.

28 Orr B, Riddick AC, Stewart GD, Anderson RA, Franco OE, Hayward SW and Thomson AA: Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate. Oncogene 31: 1130-1142, 2012.

29 Komiya E, Furuya M, Watanabe N, Miyagi Y, Higashi S and Miyazaki K: Elevated expression of angiomodulin (AGM/IGFBP-rP1) in tumour stroma and its roles in fibroblast activation. Cancer Sci 103: 691-699, 2012.

30 Pickard A, Cichon AC, Barry A, Kieran D, Patel D, Hamilton P, Salto-Tellez M, James J and McCance DJ: Inactivation of Rb in stromal fibroblasts promotes epithelial cell invasion. EMBO J 31: 3092-3103, 2012.

31 Peng M, Zhang H, Jaafar L, Risinger JI, Huang S, Mivechi NF and Ko L: Human ovarian cancer stroma contains luteinized theca cells harboring tumour suppressor gene GT198 mutations. J Biol Chem 288: 33387-33397, 2013.

32 Pula B, Wojnar A, Werynska B, Ambicka A, Kruczak A, Witkiewicz W, Ugorski M, Podhorska-Okolow M and Dziegiel P: Impact of different tumour stroma assessment methods regarding podoplanin expression on clinical outcome in patients with invasive ductal breast carcinoma. Anticancer Res 33: 1447-1455, 2013

33 Choe C, Shin YS, Kim SH, Jeon MJ, Choi SJ, Lee J and Kim J: Tumour-stromal interactions with direct cell contacts enhance motility of non-small cell lung cancer cells through the hedgehog signaling pathway. Anticancer Res 33: 3715-3723, 2013.

34 Knower KC, Chand AL, Eriksson N, Takagi K, Miki Y, Sasano H, Visvader JE, Lindeman GJ, Funder JW, Fuller PJ, Simpson ER, Tilley WD, Leedman PJ, Graham J, Muscat GE, Clarke CL and Clyne CD: Distinct nuclear receptor expression in stroma adjacent to breast tumours. Breast Cancer Res Treat 142: 211-223, 2013.

35 Wilkinson SE, Furic L, Buchanan G, Larsson O, Pedersen J, Frydenberg M, Risbridger GP and Taylor RA: Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium. Prostate 73: 1810-1823, 2013.

36 Tchou J, Zhang PJ, Bi Y, Satija C, Marjumdar R, Stephen TL, Lo A, Chen H, Mies C, June CH, Conejo-Garcia J and Puré E: Fibroblast activation protein expression by stromal cells and tumour-associated macrophages in human breast cancer. Hum Pathol 44: 2549-2557, 2013.

37 Triulzi T, Casalini P, Sandri M, Ratti M, Carcangiu ML, Colombo MP, Balsari A, Ménard S, Orlandi R and Tagliabue E: Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS One 8: e56761, 2013.

38 Valencia T, Kim JY, Abu-Baker S, Moscat-Pardos J, Ahn CS, Reina-Campos M, Duran A, Castilla EA, Metallo CM, Diaz-Meco MT and Moscat J: Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflamma-tion and tumourigenesis. Cancer Cell 26: 121-135, 2014.

39 Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M and Takeyama H: Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer 110: 469-478, 2014.

40 Miles FL and Sikes RA: Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res 12: 297-312, 2014.

41 Sano M, Driscoll DR, De Jesus-Monge WE, Klimstra DS and Lewis BC: Activated Wnt signaling in stroma contributes to development of pancreatic mucinous cystic neoplasms. Gastroenterology 146: 257-267, 2014.

42 Vaage J: Fibrosis in immune control of mammary-tumour growth. Int J Cancer 51: 325-328, 1992.

43 Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 6:392-401, 2006.

44 Baglole CJ, Ray DM, Bernstein SH, Feldon SE, Smith TJ, Sime PJ and Phipps RP: More than structural cells, fibroblasts create and orchestrate the tumour microenvironment. Immunol Invest 35: 297-325, 2006.

45 Xouri G and Christian S: Origin and function of tumour stroma fibroblasts. Semin Cell Dev Biol 21: 40-46, 2010.

46 Jacob M and E Puré: Stromal cells and tumour milieu: PDGF *et al*. In: Edited by A. Thomas-Tikhonenko, pp. 315-333, 2010, Springer Science + Business Media, New York, NY, USA.

47 Kadaba R, Birke H, Wang J, Hooper S, Andl CD, Di Maggio F, Soylu E, Ghallab M, Bor D, Froeling FE, Bhattacharya S, Rustgi AK, Sahai E, Chelala C, Sasieni P and Kocher HM.: Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol *230*: 107-117, 2013.

48 Shan LH, Sun WG, Han W, Qi L, Yang C, Chai CC, Yao K, Zhou QF, Wu HM, Wang LF and Liu JR: Roles of fibroblasts from the interface zone in invasion, migration, proliferation and apoptosis of gastric adenocarcinoma. J Clin Pathol *65*: 888-895, 2012.

49 Okamoto Y, Fujimori T, Ohkura Y, Sugai T, Arai T, Watanabe G, Wada R, Ueno H, Togashi K, Yao T, Kushima R, Mitomi H, Tomita S, Igarashi Y and Ichikawa K: Histological assessment of intra- and inter-institutional reliabilities in detection of desmoplastic reaction in biopsy specimens of early colorectal carcinomas. Pathol Int *63*: 539-545, 2013.

50 Egeblad M, Ewald AJ, Askautrud HA, Truitt ML, Welm BE, Bainbridge E, Peeters G, Krummel MF and Werb Z: Visualizing stromal cell dynamics in different tumour microenvironments by spinning disk confocal microscopy. Dis Model Mech *1*: 155-167, 2008.

51 Elenbaas B and Weinberg RA; Heterotypic signaling between epithelial tumour cells and fibroblasts in carcinoma formation. Exp Cell Res *264*: 169-184, 2001.

52 Seemayer TA, Lagacé R, Schürch W and Tremblay G: Myofibroblasts in the stroma of invasive and metastatic carcinoma: a possible host response to neoplasia. Am J Surg Pathol *3*: 525-533, 1979.

53 Rønnov-Jessen L, Petersen OW and Bissell MJ: Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev *76*: 69-125, 1996.

54 Tlsty TD and Coussens LM: Tumour stroma and regulation of cancer development. Annu Rev Pathol *1*: 119-150, 2006.

55 Abbas O and Mahalingam M: Desmoplasia: not always a bad thing. Histopathology *58*: 643-659, 2011.

56 Hartel M, Di Mola FF, Gardini A, Zimmermann A, Di Sebastiano P, Guweidhi A, Innocenti P, Giese T, Giese N, Büchler MW and Friess H: Desmoplastic reaction influences pancreatic cancer growth behaviour. World J Surg *28*: 818-825, 2004.

57 Caporale A, Vestri AR, Benvenuto E, Mariotti M, Cosenza UM, Scarpini M, Giuliani A, Mingazzini P and Angelico F: Is desmoplasia a protective factor for survival in patients with colorectal carcinoma? Clin Gastroenterol Hepatol *3*: 370-375, 2005.

58 Coulson-Thomas VJ, Coulson-Thomas YM, Gesteira TF, de Paula CA, Mader AM, Waisberg J, Pinhal MA, Friedl A, Toma L and Nader HB: Colorectal cancer desmoplastic reaction up-regulates collagen synthesis and restricts cancer cell invasion. Cell Tissue Res *346*: 223-236, 2011.

59 Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS and Kalluri R: Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell *25*: 719-734, 2014.

60 Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP and Stanger BZ: Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell *25*: 735-747, 2014.

61 Hasebe T, Mukai K, Tsuda H and Ochiai A: New prognostic histological parameter of invasive ductal carcinoma of the breast: clinicopathological significance of fibrotic focus. Pathol Int *50*: 263-272, 2000.

62 Kimura R, Fujimori T, Ichikawa K, Ajioka Y, Ueno H, Ohkura Y, Kashida H, Togashi K, Yao T, Wada R, Watanabe T, Ochiai A, Sugai T, Sugihara K and Igarashi Y: Desmoplastic reaction in biopsy specimens of early colorectal cancer: a Japanese prospective multicentre study. Pathol Int *62*: 525-531, 2012.

63 Sainio A and Järveläinen H: Extracellular matrix macromolecules in tumour microenvironment with special reference to desmoplastic reaction and the role of matrix proteoglycans and hyaluronan. J Carcinogene Mutagene S13:002, 2013.

64 Gujam FJ, Edwards J, Mohammed ZM, Going JJ and McMillan DC: The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. Br J Cancer *111*: 157-165, 2014.

65 Barth PJ, Schenck zu Schweinsberg T, Ramaswamy A and Moll R: CD34+ fibrocytes, alpha-smooth muscle antigen-positive myofibroblasts, and CD117 expression in the stroma of invasive squamous cell carcinomas of the oral cavity, pharynx, and larynx. Virchows Arch *444*: 231-234, 2004.

66 Ueno H, Jones AM, Wilkinson KH, Jass JR and Talbot IC: Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut *53*: 581-586, 2004.

67 Desmoulière A, Guyot C and Gabbiani G: The stroma reaction myofibroblast: a key player in the control of tumour cell behaviour. Int J Dev Biol *48*: 509-517, 2004.

68 Sugimoto H, Mundel TM, Kieran MW and Kalluri R: Identification of fibroblast heterogeneity in the tumour microenvironment. Cancer Biol Ther *5*: 1640-1646, 2006.

69 Gao MQ, Kim BG, Kang S, Choi YP, Park H, Kang KS and Cho NH: Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells *in vitro*. J Cell Sci *123*: 3507-3514, 2010.

70 Allen M and Louise Jones J: Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol *223*: 162-176, 2011.

71 Reinertsen T, Halgunset J, Viset T, Flatberg A, Haugsmoen LL and Skogseth H: Gene expressional changes in prostate fibroblasts from cancerous tissue. APMIS *120*: 558-571, 2012.

72 Hasebe T: Tumour-stromal interactions in breast tumour progression--significance of histological heterogeneity of tumour-stromal fibroblasts. Expert Opin Ther Targets *17*: 449-460, 2013.

73 Dotto GP: Multifocal epithelial tumours and field cancerization: stroma as a primary determinant. J Clin Invest *124*: 1446-1453, 2014.

74 Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI and West AB: Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol *277*: C1-9, 1999.

75 Bernardo ME and Fibbe WE: Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell *13*: 392-402, 2013.

76 Servais C and Erez N: From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation. J Pathol *229*: 198-207, 2013.

77 Bohonowych JE, Hance MW, Nolan KD, Defee M, Parsons CH and Isaacs JS: Extracellular Hsp90 mediates an NF-κB dependent inflammatory stromal program: implications for the prostate tumour microenvironment. Prostate *74*: 395-407, 2014.

78 Tsukada T, McNutt MA, Ross R and Gown AM: HHF35, a muscle actin-specific monoclonal antibody. II. Reactivity in normal, reactive, and neoplastic human tissues. Am J Pathol *127*: 389-402, 1987.

79 Barron DA and Rowley DR: The reactive stroma micro-environment and prostate cancer progression. Endocr Relat Cancer *19*: R187-204, 2012.

80 Hoffman RM: Stromal-cell and cancer-cell exosomes leading the metastatic exodus for the promised niche. Breast Cancer Res *15*: 310, 2013.

81 Koperek O, Asari R, Niederle B and Kaserer K: Desmoplastic stromal reaction in papillary thyroid microcarcinoma. Histopathology *58*: 919-924, 2011.

82 Dabbous MK, Haney L, Carter LM, Paul AK and Reger J: Heterogeneity of fibroblast response in host-tumour cell-cell interactions in metastatic tumours. J Cell Biochem *35*: 333-344, 1987.

83 Grégoire M and Lieubeau B: The role of fibroblasts in tumour behaviour. In: Cancer and Metastasis Reviews 14: 339-350, 1995, Kluwer Academic Publishers, Netherlands.

84 Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I and Busund LT: The role of tumour stroma in cancer progression and prognosis: Emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol *6*: 209-217, 2011.

85 De Sousa E Melo F, Vermeulen L, Fessler E and Medema JP: Cancer heterogeneity--a multifaceted view. EMBO Rep *14*: 686-695, 2013.

86 Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoulière A, Varga J, De Wever O, Mareel M and Gabbiani G: Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol *180*: 1340-1355, 2012.

87 Gravina GL, Mancini A, Ranieri G, Di Pasquale B, Marampon F, Di Clemente L, Ricevuto E and Festuccia C: Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. Int J Oncol *42*: 2116-2122, 2013.

88 Eyden B, Banerjee SS, Shenjere P and Fisher C: The myofibroblast and its tumours. J Clin Pathol *62*: 236-249, 2009.

89 Eyden B, Curry A and Wang G: Stromal cells in the human gut show ultrastructural features of fibroblasts and smooth muscle cells but not myofibroblasts. J Cell Mol Med *15*: 1483-1491, 2011.

90 Fu S, Dong L, Sun W, Xu Y, Gao L and Miao Y: Stromal–epithelial crosstalk provides a suitable micro-environment for the progression of ovarian cancer cells *in vitro*. Cancer Invest *31*: 616-624, 2013.

91 San Martin R, Barron DA, Tuxhorn JA, Ressler SJ, Hayward SW, Shen X, Laucirica R, Wheeler TM, Gutierrez C, Ayala GE, Ittmann M and Rowley DR: Recruitment of CD34(+) fibroblasts in tumour-associated reactive stroma: the reactive microvasculature hypothesis. Am J Pathol *184*: 1860-1870, 2014.

92 Öhlund D, Elyada E and Tuveson D: Fibroblast heterogeneity in the cancer wound. J Exp Med *211*: 1503-1523, 2014.

93 Hu M, Yao J, Cai L, Bachman KE, van den Brûle F, Velculescu V and Polyak K: Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet *37*: 899-905, 2005.

94 Jiang L, Gonda TA, Gamble MV, Salas M, Seshan V, Tu S, Twaddell WS, Hegyi P, Lazar G, Steele I, Varro A, Wang TC and Tycko B: Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res *68*: 9900-9908, 2008.

95 Hinz B and Gabbiani G: Fibrosis: recent advances in myofibroblast biology and new therapeutic perspectives. F1000 Biol Rep *2*: 78, 2010.

96 Cirri P and Chiarugi P: Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res *1*: 482-497, 2011.

97 Worthley DL, Si Y, Quante M, Churchill M, Mukherjee S and Wang TC: Bone marrow cells as precursors of the tumour stroma. Exp Cell Res *319*: 1650-1656, 2013.

98 Madar S, Goldstein I and Rotter V: 'Cancer associated fibroblasts' – more than meets the eye. Trends Mol Med *19*: 447-453, 2013.

99 Petersson F, Branzovsky J, Martinek P, Korabecna M, Kruslin B, Hora M, Peckova K, Bauleth K, Pivovarcikova K, Michal M, Svajdler M, Sperga M, Bulimbasic S, Leroy X, Rychly B, Trivunic S, Kokoskova B, Rotterova P, Podhola M, Suster S and Hes O: The leiomyomatous stroma in renal cell carcinomas is polyclonal and not part of the neoplastic process. Virchows Arch *465*: 89-96, 2014.

100 Shukla A, Edwards R, Yang Y, Hahn A, Folkers K, Ding J, Padmakumar VC, Cataisson C, Suh KS and Yuspa SH: CLIC4 regulates TGF-β-dependent myofibroblast differentiation to produce a cancer stroma. Oncogene *33*: 842-850, 2014.

101 Franks AL and Slansky JE: Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res *32*: 1119-1136, 2012.

102 Reagan MR and Kaplan DL: Concise review: Mesenchymal stem cell tumour-homing: detection methods in disease model systems. Stem Cells *29*: 920-927, 2011.

103 Lavoie JR and Rosu-Myles M: Uncovering the secretes of mesenchymal stem cells. Biochimie *95*: 2212-2221, 2013.

104 Nizzardo M, Simone C, Falcone M, Riboldi G, Comi GP, Bresolin N and Corti S: Direct reprogramming of adult somatic cells into other lineages: past evidence and future perspectives. Cell Transplant *22*: 921-944, 2013.

105 Haniffa MA, Collin MP, Buckley CD and Dazzi F: Mesenchymal stem cells: the fibroblasts' new clothes? Haematologica *94*: 258-263, 2009.

106 Bae S, Ahn JH, Park CW, Son HK, Kim KS, Lim NK, Jeon CJ and Kim H: Gene and microRNA expression signatures of human mesenchymal stromal cells in comparison to fibroblasts. Cell Tissue Res *335*: 565-573, 2009.

107 Alt E, Yan Y, Gehmert S, Song YH, Altman A, Gehmert S, Vykoukal D and Bai X: Fibroblasts share mesenchymal phenotypes with stem cells, but lack their differentiation and colony-forming potential. Biol Cell *103*: 197-208, 2011.

108 Strioga M, Viswanathan S, Darinskas A, Slaby O and Michalek J: Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev *21*: 2724-2752, 2012.

109 Hematti P: Mesenchymal stromal cells and fibroblasts: a case of mistaken identity? Cytotherapy *14*: 516-521, 2012.

110 Sensebé L, Tarte K, Galipeau J, Krampera M, Martin I, Phinney DG, Shi Y and MSC Committee of the International Society for Cellular Therapy.: Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell *10*: 9-10, 2012.

111 Becker JC, Andersen MH, Schrama D and Thor Straten P: Immune-suppressive properties of the tumour microenvironment. Cancer Immunol Immunother *62*: 1137-1148, 2013.

112 Unsworth A, Anderson R and Britt K: Stromal fibroblasts and the immune microenvironment: partners in mammary gland biology and pathology? J Mammary Gland Biol Neoplasia *19*: 169-182, 2014.

113 Gao L, Liu F, Tan L, Liu T, Chen Z and Shi C: The immunosuppressive properties of non-cultured dermal-derived mesenchymal stromal cells and the control of graft-versus-host disease. Biomaterials *35*: 3582-3588, 2014.

114 Follonier Castella L, Gabbiani G, McCulloch CA and Hinz B: Regulation of myofibroblast activities: calcium pulls some strings behind the scene. Exp Cell Res *316*: 2390-2401, 2010.

115 Shohara R, Yamamoto A, Takikawa S, Iwase A, Hibi H, Kikkawa F and Ueda M: Mesenchymal stromal cells of human umbilical cord Wharton's jelly accelerate wound healing by paracrine mechanisms. Cytotherapy *14*: 1171-1181, 2012.

116 Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW and Banerjee D: Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res *68*: 4331-4339, 2008.

117 Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, Scheding S and Bengzon J: Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther *17*: 183-190, 2009.

118 Spencer ND, Gimble JM and Lopez MJ: Mesenchymal stromal cells: past, present, and future. Vet Surg 40: 129-139, 2011.

119 Delinassios JG and Kottaridis SD: Interactions between human fibroblasts and HeLa cells *in vitro*. Biol Cell *50*: 9-16, 1984.

120 Barcellos-de-Souza P, Gori V, Bambi F and Chiarugi P: Tumour microenvironment: bone marrow-mesenchymal stem cells as key players. Biochim Biophys Acta *1836*: 321-335, 2013.

121 Uchibori R, Tsukahara T, Mizuguchi H, Saga Y, Urabe M, Mizukami H, Kume A and Ozawa K: NF-κB activity regulates mesenchymal stem cell accumulation at tumour sites. Cancer Res *73*: 364-372, 2013.

122 Vegh I, Grau M, Gracia M, Grande J, de la Torre P and Flores AI: Decidua mesenchymal stem cells migrated toward mammary tumours *in vitro* and *in vivo* affecting tumour growth and tumour development. Cancer Gene Ther *20*: 8-16, 2013.

123 Jones S, Horwood N, Cope A, and Dazzi F: The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol *179*: 2824-2831, 2007.

124 Li L, Tian H, Chen Z, Yue W, Li S and Li W: Inhibition of lung cancer cell proliferation mediated by human mesenchymal stem cells. Acta Biochim Biophys Sin (Shanghai) *43*: 143-148, 2011.

125 Rønnov-Jessen L, van Deurs B, Celis JE and Petersen OW: Smooth muscle differentiation in cultured human breast gland stromal cells. Lab Invest *63*: 532-543, 1990.

126 Rønnov-Jessen L, Van Deurs B, Nielsen M and Petersen OW: Identification, paracrine generation, and possible function of human breast carcinoma myofibroblasts in culture. In Vitro Cell Dev Biol *28A*: 273-83, 1992.

127 Rønnov-Jessen L, Petersen OW, Koteliansky VE and Bissell MJ: The origin of the myofibroblasts in breast cancer. Recapitulation of tumour environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest *95*: 859-873, 1995.

128 Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR and Polyak K: Molecular characterization of the tumour microenvironment in breast cancer. Cancer Cell *6*: 17-32, 2004.

129 Orimo A and Weinberg RA: Heterogeneity of stromal fibroblasts in tumours. Cancer Biol Ther *6*: 618-619, 2007.

130 Labiche A, Heutte N, Herlin P, Chasle J, Gauduchon P and Elie N: Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma. Int J Gynecol Cancer *20*: 28-33, 2010.

131 Dvorak HF, Weaver VM, Tlsty TD and Bergers G: Tumour microenvironment and progression. J Surg Oncol *103*: 468-474, 2011.

132 Thode C, Jørgensen TG, Dabelsteen E, Mackenzie I and Dabelsteen S: Significance of myofibroblasts in oral squamous cell carcinoma. J Oral Pathol Med *40*: 201-207, 2011.

133 Kiskowski MA, Jackson RS 2nd, Banerjee J, Li X, Kang M, Iturregui JM, Franco OE, Hayward SW and Bhowmick NA: Role for stromal heterogeneity in prostate tumourigenesis. Cancer Res *71*: 3459-3470, 2011.

134 Delinassios JG, Kottaridis SD and Garas J: Uncontrolled growth of tumour stromal fibroblasts *in vitro*. Exp Cell Biol *51*: 201-209, 1983.

135 Cukierman E and Bassi DE: Physico-mechanical aspects of extracellular matrix influences on tumourigenic behaviours. Semin Cancer Biol *20*: 139-145, 2010.

136 Serini G and Gabbiani G: Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res *250*: 273-283, 1999.

137 Takahashi A, Ishii G, Kinoshita T, Yoshida T, Umemura S, Hishida T, Yoh K, Niho S, Goto K, Ohmatsu H, Ohe Y, Nagai K and Ochiai A: Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine carcinomas of the lung. J Cancer Res Clin Oncol *139*: 1869-1878, 2013.

138 Wegmeyer H, Bröske AM, Leddin M, Kuentzer K, Nisslbeck AK, Hupfeld J, Wiechmann K, Kuhlen J, von Schwerin C, Stein C, Knothe S, Funk J, Huss R and Neubauer M: Mesenchymal stromal cell characteristics vary depending on their origin. Stem Cells Dev *22*: 2606-2618, 2013.

139 Sorrell JM and Caplan AI: Fibroblast heterogeneity: more than skin deep. J Cell Sci *117*: 667-675, 2004.

140 Jelaska A, Strehlow D and Korn JH: Fibroblast heterogeneity in physiological conditions and fibrotic disease. Springer Semin Immunopathol *21*: 385-395, 1999.

141 Peng YC, Levine CM, Zahid S, Wilson EL and Joyner AL: Sonic hedgehog signals to multiple prostate stromal stem cells that replenish distinct stromal subtypes during regeneration. Proc Natl Acad Sci USA *110*: 20611-20616, 2013.

142 Delinassios JG: Prolonged *in vitro* maintenance of human diploid fibroblasts in a new tissue culture medium (PRC-1). Expl Cell Biol *51*: 315-321, 1983.

143 Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I and Campbell IG: No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet *40*: 650-655, 2008.

144 Walter K, Omura N, Hong SM, Griffith M and Goggins M: Pancreatic cancer associated fibroblasts display normal allelotypes. Cancer Biol Ther 7: 882-888, 2008.

145 Corver WE, Ter Haar NT, Fleuren GJ and Oosting J: Cervical carcinoma-associated fibroblasts are DNA diploid and do not show evidence for somatic genetic alterations. Cell Oncol (Dordr) 34: 553-563, 2011.

146 Watson CJ and Khaled WT: Mammary development in the embryo and adult: a journey of morphogenesis and commitment. Development 135: 995-1003, 2008.

147 Lühr I, Friedl A, Overath T, Tholey A, Kunze T, Hilpert F, Sebens S, Arnold N, Rösel F, Oberg HH, Maass N, Mundhenke C, Jonat W and Bauer M: Mammary fibroblasts regulate morphogenesis of normal and tumourigenic breast epithelial cells by mechanical and paracrine signals. Cancer Lett 325: 175-188, 2012.

148 Sakakura T, Suzuki Y and Shiurba R: Mammary stroma in development and carcinogenesis. J Mammary Gland Biol Neoplasia 18: 189-197, 2013.

149 Chen JC, Erikson DW, Piltonen TT, Meyer MR, Barragan F, McIntire RH, Tamaresis JS, Vo KC, Giudice LC and Irwin JC: Coculturing human endometrial epithelial cells and stromal fibroblasts alters cell-specific gene expression and cytokine production. Fertil Steril 100: 1132-1143, 2013.

150 Cunha GR and Ricke WA: A historical perspective on the role of stroma in the pathogenesis of benign prostatic hyperplasia. Differentiation 82: 168-172, 2011.

151 Nakamura Y, Ishikawa H, Kawai K, Tabata Y and Suzuki S: Enhanced wound healing by topical administration of mesenchymal stem cells transfected with stromal cell-derived factor-1. Biomaterials 34: 9393-9400, 2013.

152 Otranto M, Sarrazy V, Bonté F, Hinz B, Gabbiani G and Desmoulière A: The role of the myofibroblast in tumour stroma remodeling. Cell Adh Migr 6: 203-219, 2012.

153 Kramann R, DiRocco DP and Humphreys BD: Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease. J Pathol 231: 273-289, 2013.

154 Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C and Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3: 349-363, 2002.

155 Lim KP, Cirillo N, Hassona Y, Wei W, Thurlow JK, Cheong SC, Pitiyage G, Parkinson EK and Prime SS: Fibroblast gene expression profile reflects the stage of tumour progression in oral squamous cell carcinoma. J Pathol 223: 459-469, 2011.

156 Bornstein R, Macias MI, de la Torre P, Grande J and Flores AI: Human decidua-derived mesenchymal stromal cells differentiate into hepatic-like cells and form functional three-dimensional structures. Cytotherapy 14: 1182-1192, 2012.

157 Schmitt-Gräff A, Desmoulière A and Gabbiani G: Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity. Virchows Arch 425: 3-24, 1994.

158 Desmoulière A, Chaponnier C and Gabbiani G: The evolution of the concept of myofibroblast: Implications for normal and pathological tissue remodeling. In: Tissue Repair, Contraction and the Myofibroblast. Edited by C. Chaponnier, A. Desmoulière and G. Gabbiani, pp. 1-6, 2006, Landes Bioscience and Springer Science+Business Media, LLC - Springer USA.

159 Hayward SW, Cunha GR and Dahiya R: Normal development and carcinogenesis of the prostate. A unifying hypothesis. Ann NY Acad Sci 784: 50-62, 1996.

160 Muschler J and Streuli CH: Cell-matrix interactions in mammary gland development and breast cancer. Cold Spring Harb Perspect Biol 2: a003202, 2010.

161 Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H, Chong JL, Naidu S, Wei G, Sharma SM, Stephens JA, Fernandez SA, Gurcan MN, Weinstein MB, Barsky SH, Yee L, Rosol TJ, Stromberg PC, Robinson ML, Pepin F, Hallett M, Park M, Ostrowski MC and Leone G: Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461: 1084-1091, 2009.

162 Tremblay G: Stromal aspects of breast carcinoma. Exp Mol Pathol 31: 248-260, 1979.

163 Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC and Chung LW: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54: 2577-2581, 1994.

164 Hofland LJ, van der Burg B, van Eijck CH, Sprij DM, van Koetsveld PM and Lamberts SW: Role of tumour-derived fibroblasts in the growth of primary cultures of human breast-cancer cells: effects of epidermal growth factor and the somatostatin analogue octreotide. Int J Cancer 60: 93-99, 1995.

165 Hung SC, Deng WP, Yang WK, Liu RS, Lee CC, Su TC, Lin RJ, Yang DM, Chang CW, Chen WH, Wei HJ and Gelovani JG: Mesenchymal stem cell targeting of microscopic tumours and tumour stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res 11: 7749-7756, 2005.

166 Guo X, Oshima H, Kitmura T, Taketo MM and Oshima M: Stromal fibroblasts activated by tumour cells promote angiogenesis in mouse gastric cancer. J Biol Chem 283: 19864-19871, 2008.

167 Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R and Burow ME: Adult human mesenchymal stem cells enhance breast tumourigenesis and promote hormone independence. Breast Cancer Res Treat 121: 293-300, 2010.

168 Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L and Chiarugi P: Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 70: 6945-6956, 2010.

169 Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D and Jain RK: Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci USA 107: 21677-21682, 2010.

170 Mishra P, Banerjee D and Ben-Baruch A: Chemokines at the crossroads of tumour-fibroblast interactions that promote malignancy. J Leukoc Biol 89: 31-39, 2011.

171 Giannoni E, Bianchini F, Calorini L and Chiarugi P: Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid Redox Signal 14: 2361-2371, 2011.

172 Palumbo A Jr., Ferreira LB, Reis de Souza PA, Oliveira FL, Pontes B, Viana NB, Machado DE, Palmero CY, Alves LM, Gimba ER and Nasciutti LE: Extracellular matrix secreted by reactive stroma is a main inducer of pro-tumourigenic features on LNCaP prostate cancer cells. Cancer Lett 321: 55-64, 2012.

173 Strell C, Rundqvist H and Ostman A: Fibroblasts – a key host cell type in tumour initiation, progression, and metastasis. Ups J Med Sci 117: 187-195, 2012.

174 Raz Y and Erez N: An inflammatory vicious cycle: Fibroblasts and immune cell recruitment in cancer. Exp Cell Res 319: 1596-1603, 2013.

175 Varzavand A, Drake JM, Svensson RU, Herndon ME, Zhou B, Henry MD and Stipp CS: Integrin α3β1 regulates tumour cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization. Clin Exp Metastasis 30: 541-552, 2013.

176 Togo S, Polanska UM, Horimoto Y and Orimo A: Carcinoma-associated fibroblasts are a promising therapeutic target. Cancers (Basel) 5: 149-169, 2013.

177 Pasquet M, Golzio M, Mery E, Rafii A, Benabbou N, Mirshahi P, Hennebelle I, Bourin P, Allal B, Teissie J, Mirshahi M and Couderc B: Hospicells (ascites-derived stromal cells) promote tumourigenicity and angiogenesis. Int J Cancer 126: 2090-2101, 2010.

178 Kim E, Rebecca V, Fedorenko IV, Messina JL, Mathew R, Maria-Engler SS, Basanta D, Smalley KS and Anderson AR: Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach. Cancer Res 73: 6874-6885, 2013.

179 Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W, Upile T, Kalavrezos N, Violette SM, Weinreb PH, Chester KA, Chana JS, Marshall JF, Hart IR, Hackshaw AK, Piper K and Thomas GJ: Stromal features are predictive of disease mortality in oral cancer patients. J Pathol 223: 470-481, 2011.

180 DeCosse JJ, Gossens CL, Kuzma JF and Unsworth BR: Breast cancer: induction of differentiation by embryonic tissue. Science 181: 1057-1058, 1973.

181 DeCosse JJ, Gossens C, Kuzma JF and Unsworth BR: Embryonic inductive tissues that cause histologic differentiation of murine mammary carcinoma in vitro. J Nat Cancer Inst 54: 913-922, 1975.

182 Kirk D, Szalay MF and Kaighn ME: Modulation of growth of a human prostatic cancer cell line (PC-3) in agar culture by normal human lung fibroblasts. Cancer Res 41: 1100-1103, 1981.

183 Imanishi J, Hoshino S, Matsuoka H, Uemura H, Imanishi T, Tanaka A, Nishino H and Kishida T: Tumour degeneration by human embryonic fibroblasts and its enhancement by interferon. Cancer Res 43: 4323-4326, 1983.

184 Kirk D, Kagawa S and Vener G: Comparable growth regulation of five human tumour cell lines by neonatal human lung fibroblasts in semisolid culture media. Cancer Res 43: 3754-3758, 1983.

185 Wu KF, Pope JH and Ellem KA: Inhibition of growth of certain human tumour cell lines by a factor derived from human fibroblast-like cell lines. I. Demonstration by mixed culture and by use of cell washings. Int J Cancer 35: 477-482, 1985.

186 Delinassios JG: Cytocidal effects of human fibroblasts on HeLa cells in vitro. Biol Cell 59: 69-77, 1987.

187 Adams EF, Newton CJ, Tait GH, Braunsberg H, Reed MJ and James VH: Paracrine influence of human breast stromal fibroblasts on breast epithelial cells: secretion of a polypeptide which stimulates reductive 17 beta-oestradiol dehydrogenase activity. Int J Cancer 42: 119-122, 1988.

188 Shirasuna K, Morioka S, Watatani K, Hayashido Y, Furusawa H, Sugiyama M, Okura M and Matsuya T: Growth inhibition and differentiation of human salivary adenocarcinoma cells by medium conditioned with normal human fibroblasts. Cancer Res 48: 2819-2824, 1988.

189 Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J and Kerbel RS: Fibroblast cell interactions with human melanoma cells affect tumour cell growth as a function of tumour progression. Proc Natl Acad Sci USA 88: 6028-6032, 1991.

190 Benathan M, Pararas C and Frenk E: Modulatory growth effects of 3T3 fibroblasts on cocultivated human melanoma cells. Anticancer Res 11: 203-207, 1991.

191 Kirk D, Broberg T, Irwin JC, Kenney WC and Jones LW: Fibroblast inhibition of tumour cells may be mediated by TGF-beta 1. In Vitro Cell Dev Biol 29A: 4-6, 1993.

192 Karlan BY, Baldwin RL, Cirisano FD, Mamula PW, Jones J and Lagasse LD: Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation. Gynecol Oncol 59: 67-74, 1995.

193 Verfaillie C and Catanzaro P: Direct contact with stroma inhibits proliferation of human long-term culture initiating cells. Leukemia 10: 498-504, 1996.

194 Bauer G: Elimination of transformed cells by normal cells: a novel concept for the control of carcinogenesis. Histol Histopathol 11: 237-255, 1996.

195 Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak MP, Millot G, de Cremoux P and Calvo F: Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 68: 207-214, 1996.

196 Dong-Le Bourhis X, Berthois Y, Millot G, Degeorges A, Sylvi M, Martin PM and Calvo F: Effect of stromal and epithelial cells derived from normal and tumourous breast tissue on the proliferation of human breast cancer cell lines in co-culture. Int J Cancer 71: 42-48, 1997.

197 Kooistra A, Romijn JC and Schröder FH: Stromal inhibition of epithelial cell growth in the prostate; overview of an experimental study. Urol Res 25: S97-105, 1997.

198 Komarova EA, Diatchenko L, Rokhlin OW, Hill JE, Wang ZJ, Krivokrysenko VI, Feinstein E and Gudkov AV: Stress-induced secretion of growth inhibitors: a novel tumour suppressor function of p53. Oncogene 17: 1089-1096, 1998.

199 Javaherian A, Vaccariello M, Fusenig NE and Garlick JA: Normal keratinocytes suppress early stages of neoplastic progression in stratified epithelium. Cancer Res 58: 2200-2208, 1998.

200 Ahn J-O, Coh Y-R, Lee H-W, Shin I-S, Kang S-K, Youn H-Y: Human adipose tissue-derived mesenchymal stem cells inhibit melanoma gowth in vitro and in vivo. Anticancer Res 35: 159-168, 2015.

201 Kawada M, Ishizuka M and Takeuchi T: Enhancement of antiproliferative effects of interleukin-1beta and tumour necrosis factor-alpha on human prostate cancer LNCaP cells by coculture with normal fibroblasts through secreted interleukin-6. Jpn J Cancer Res 90: 546-554, 1999.

202 Ohlsson LB, Varas L, Kjellman C, Edvardsen K and Lindvall M: Mesenchymal progenitor cell-mediated inhibition of tumour growth in vivo and in vitro in gelatin matrix. Exp Mol Pathol 75: 248-255, 2003.

203 Paraguassú-Braga FH, Borojevic R, Bouzas LF, Barcinski MA and Bonomo A: Bone marrow stroma inhibits proliferation and apoptosis in leukemic cells through gap junction-mediated cell communication. Cell Death Differ *10*: 1101-1108, 2003.

204 Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG and Moses HL: TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science *303*: 848-851, 2004.

205 Wang T, Xia D, Li N, Wang C, Chen T, Wan T, Chen G and Cao X: Bone marrow stromal cell-derived growth inhibitor inhibits growth and migration of breast cancer cells via induction of cell cycle arrest and apoptosis. J Biol Chem *280*: 4374-4382, 2005.

206 Proia DA and Kuperwasser C: Stroma: tumour agonist or antagonist. Cell Cycle *4*: 1022-1025, 2005.

207 Sadlonova A, Novak Z, Johnson MR, Bowe DB, Gault SR, Page GP, Thottassery JV, Welch DR and Frost AR: Breast fibroblasts modulate epithelial cell proliferation in three-dimensional *in vitro* co-culture. Breast Cancer Res *7*: R46-59, 2005.

208 Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M and Finkel T: Human mesenchymal stem cells exert potent antitumourigenic effects in a model of Kaposi's sarcoma. J Exp Med *203*: 1235-1247, 2006.

209 Kenny HA, Krausz T, Yamada SD and Lengyel E: Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer *121*: 1463-1472, 2007.

210 Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, Ye L and Zhang X: Suppression of tumourigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res *18*: 500-507, 2008.

211 Postovit LM, Margaryan NV, Seftor EA, Kirschmann DA, Lipavsky A, Wheaton WW, Abbott DE, Seftor RE and Hendrix MJ: Human embryonic stem cell microenvironment suppresses the tumourigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci USA *105*: 4329-4334, 2008.

212 Qiao L, Xu ZL, Zhao TJ, Ye LH and Zhang X: Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett *269*: 67-77, 2008.

213 Lee JJ, Perera RM, Wang H, Wu DC, Liu XS, Han S, Fitamant J, Jones PD, Ghanta KS, Kawano S, Nagle JM, Deshpande V, Boucher Y, Kato T, Chen JK, Willmann JK, Bardeesy N and Beachy PA: Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci USA *111*: E3091-3100, 2014.

214 Ostman A and Augsten M: Cancer-associated fibroblasts and tumour growth – bystanders turning into key players. Curr Opin Genet Dev *19*: 67-73, 2009.

215 Paland N, Kamer I, Kogan-Sakin I, Madar S, Goldfinger N and Rotter V: Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an *in vitro* cocultivation model of prostate cancer. Mol Cancer Res *7*: 1212-1223, 2009.

216 Zhu Y, Sun Z, Han Q, Liao L, Wang J, Bian C, Li J, Yan X, Liu Y, Shao C and Zhao RC: Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia *23*: 925-933, 2009.

217 Rodrigues-Lisoni FC, Peitl P Jr, Vidotto A, Polachini GM, Maniglia JV, Carmona-Raphe J, Cunha BR, Henrique T, Souza CF, Teixeira RA, Fukuyama EE, Michaluart P Jr, de Carvalho MB, Oliani SM; Head and Neck Genome Project GENCAPO, Tajara EH, Cury PM, de Carvalho MB, Dias-Neto E, Figueiredo DL, Fukuyama EE, Góis-Filho JF, Leopoldino AM, Mamede RC, Michaluart-Junior P, Moyses RA, Nóbrega FG, Nóbrega MP, Nunes FD, Ojopi EF, Serafini LN, Severino P, Silva AM, Silva WA Jr, Silveira NJ, Souza SC, Tajara EH, Wünsch-Filho V, Amar A, Bandeira CM, Braconi MA, Brandão LG, Brandão RM, Canto AL, Cerione M, Cicco R, Chagas MJ, Chedid H, Costa A, Cunha BR, Curioni OA, Fortes CS, Franzi SA, Frizzera AP, Gazito D, Guimarães PE, Kaneto CM, López RV, Macarenco R, Magalhães MR, Meneses C, Mercante AM, Pinheiro DG, Polachini GM, Rapoport A, Rodini CO, Rodrigues-Lisoni FC, Rodrigues RV, Rossi L, Santos AR, Santos M, Settani F, Silva FA, Silva IT, Souza TB, Stabenow E, Takamori JT, Valentim PJ, Vidotto A, Xavier FC, Yamagushi F, Cominato ML, Correa PM, Mendes GS, Paiva R, Ramos O, Silva C, Silva MJ and Tarlá MV: Genomics and proteomics approaches to the study of cancer-stroma interactions. BMC Med Genomics *3*: 14, 2010.

218 Sun B, Yu KR, Bhandari DR, Jung JW, Kang SK and Kang KS: Human umbilical cord blood mesenchymal stem cell-derived extracellular matrix prohibits metastatic cancer cell MDA-MB-231 proliferation. Cancer Lett *296*: 178-185, 2010.

219 Martin FT, Dwyer RM, Kelly J, Khan S, Murphy JM, Curran C, Miller N, Hennessy E, Dockery P, Barry FP, O'Brien T and Kerin MJ: Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat *124*: 317-326, 2010.

220 Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, Srinivasan R, Trimboli AJ, Martin CK, Li F, Yu L, Fernandez SA, Pécot T, Rosol TJ, Cory S, Hallett M, Park M, Piper MG, Marsh CB, Yee LD, Jimenez RE, Nuovo G, Lawler SE, Chiocca EA, Leone G and Ostrowski MC: Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol *14*: 159-167, 2011.

221 Berdiel-Acer M, Bohem ME, López-Doriga A, Vidal A, Salazar R, Martínez-Iniesta M, Santos C, Sanjuan X, Villanueva A and Molleví DG: Hepatic carcinoma-associated fibroblasts promote an adaptative response in colorectal cancer cells that inhibit proliferation and apoptosis: nonresistant cells die by nonapoptotic cell death. Neoplasia *13*: 931-946, 2011.

222 Dai LJ, Moniri MR, Zeng ZR, Zhou JX, Rayat J and Warnock GL: Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett *305*: 8-20, 2011.

223 Jin C, Yang C, Wu X, Wang F and McKeehan WL: FGFR3-expressing smooth muscle-like stromal cells differentiate in response to FGFR2IIIb-expressing prostate tumour cells and delay tumour progression. In Vitro Cell Dev Biol Anim *47*: 500-505, 2011.

224 Chang PH, Hwang-Verslues WW, Chang YC, Chen CC, Hsiao M, Jeng YM, Chang KJ, Lee EY, Shew JY and Lee WH: Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumourigenesis via blocking PI3K/Akt/β-catenin pathway. Cancer Res *72*: 4652-4661, 2012.

225 Ma Y, Hao X, Zhang S and Zhang J: The *in vitro* and *in vivo* effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells. Breast Cancer Res Treat *133*: 473-485, 2012.

226 Sun XY, Nong J, Qin K, Lu H, Moniri MR, Dai LJ and Warnock GL: MSC(TRAIL)-mediated HepG2 cell death in direct and indirect co-cultures. Anticancer Res *31*: 3705-3712, 2011.

227 Senst C, Nazari-Shafti T, Kruger S, Höner Zu Bentrup K, Dupin CL, Chaffin AE, Srivastav SK, Wörner PM, Abdel-Mageed AB, Alt EU and Izadpanah R: Prospective dual role of mesenchymal stem cells in breast tumour microenvironment. Breast Cancer Res Treat *137*: 69-79, 2013.

228 Manov I, Hirsh M, Iancu TC, Malik A, Sotnichenko N, Band M, Avivi A and Shams I: Pronounced cancer resistance in a subterranean rodent, the blind mole-rat, Spalax: *in vivo* and *in vitro* evidence. BMC Biol *11*: 91, 2013.

229 Dumont N, Liu B, Defilippis RA, Chang H, Rabban JT, Karnezis AN, Tjoe JA, Marx J, Parvin B and Tlsty TD: Breast fibroblasts modulate early dissemination, tumourigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia *15*: 249-262, 2013.

230 Shao H, Cai L, Grichnik JM, Livingstone AS, Velazquez OC and Liu ZJ: Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. Oncogene *30*: 4316-4326, 2011.

231 Hayashi N and Cunha GR: Mesenchyme-induced changes in the neoplastic characteristics of the Dunning prostatic adenocarcinoma. Cancer Res *51*: 4924-4930, 1991.

232 Lu C, Vickers MF and Kerbel RS: Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumour progression. Proc Natl Acad Sci USA *89*: 9215-9219, 1992.

233 Cunha GR: Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer *74(3 Suppl)*: 1030-1044, 1994.

234 Cunha GR, Hayward SW, Wang YZ and Ricke WA: Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer *107*: 1-10, 2003.

235 Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D and Dazzi F: Mesenchymal stem cells inhibit proliferation and apoptosis of tumour cells: impact on *in vivo* tumour growth. Leukemia *21*: 304-310, 2007.

236 Sun B, Roh KH, Park JR, Lee SR, Park SB, Jung JW, Kang SK, Lee YS and Kang KS: Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy *11*: 289-298, 2009.

237 Cousin B, Ravet E, Poglio S, De Toni F, Bertuzzi M, Lulka H, Touil I, André M, Grolleau JL, Péron JM, Chavoin JP, Bourin P, Pénicaud L, Casteilla L, Buscail L and Cordelier : Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both *in vitro* and *in vivo*. PLoS One *4*: e6278, 2009.

238 Reimann M, Lee S, Loddenkemper C, Dörr JR, Tabor V, Aichele P, Stein H, Dörken B, Jenuwein T and Schmitt CA: Tumour stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell *17*: 262-272, 2010.

239 Li GC, Ye QH, Xue YH, Sun HJ, Zhou HJ, Ren N, Jia HL, Shi J, Wu JC, Dai C, Dong QZ and Qin LX: Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97-H cell line. Cancer Sci *101*: 2546-2553, 2010.

240 Ling X, Marini F, Konopleva M, Schober W, Shi Y, Burks J, Clise-Dwyer K, Wang RY, Zhang W, Yuan X, Lu H, Caldwell L and Andreeff M: Mesenchymal Stem Cells Overexpressing IFN-β Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumour Model. Cancer Microenviron *3*: 83-95, 2010.

241 Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, Shi Y, Abbruzzese J, Konopleva M, Andreeff M and Marini FC: Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumours *in vivo*, an effect countered by anti-inflammatory treatment. Cytotherapy *12*: 615-625, 2010.

242 Li Y, Zhao Y, Cheng Z, Zhan J, Sun X, Qian H, Zhu W and Xu W: Mesenchymal stem cell-like cells from children foreskin inhibit the growth of SGC-7901 gastric cancer cells. Exp Mol Pathol *94*: 430-437, 2013.

243 Takahara K, Ii M, Inamoto T, Komura K, Ibuki N, Minami K, Uehara H, Hirano H, Nomi H, Kiyama S, Asahi M and Azuma H: Adipose-derived stromal cells inhibit prostate cancer cell proliferation inducing apoptosis. Biochem Biophys Res Commun *446*: 1102-1107, 2014.

244 Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A and Weinberg RA: Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA *101*: 4966-4971, 2004.

245 Brouty-Boyé D, Mainguené C, Magnien V, Israel L and Beaupain R: Fibroblast-mediated differentiation in human breast carcinoma cells (MCF-7) grown as nodules *in vitro*. Int J Cancer *56*: 731-735, 1994.

246 Shekhar MP, Werdell J, Santner SJ, Pauley RJ and Tait L: Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumour development and progression. Cancer Res *61*: 1320-1326, 2001.

247 Parrinello S, Coppe JP, Krtolica A and Campisi J: Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci *118*: 485-496, 2005.

248 Maffini MV, Calabro JM, Soto AM and Sonnenschein C: Stromal regulation of neoplastic development: age-dependent normalization of neoplastic mammary cells by mammary stroma. Am J Pathol *167*: 1405-1410, 2005.

249 Römer AM, Lühr I, Klein A, Friedl A, Sebens S, Rösel F, Arnold N, Strauss A, Jonat W and Bauer M: Normal mammary fibroblasts induce reversion of the malignant phenotype in human primary breast cancer. Anticancer Res *33*: 1525-1536, 2013.

250 Franses JW, Baker AB, Chitalia VC and Edelman ER: Stromal endothelial cells directly influence cancer progression. Sci Transl Med *3*: 66ra5, 2011.

251 Bissell MJ and Hines WC: Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med *17*: 320-329, 2011.

252 Grotendorst GR, Rahmanie H and Duncan MR: Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J *18*: 469-479, 2004.

253 Rossi L, Reverberi D, Capurro C, Aiello C, Cipolla M, Bonanno M and Podestà G: Fibroblasts regulate the migration of MCF7 mammary carcinoma cells in hydrated collagen gel. Anticancer Res *14*: 1493-1501, 1994.

254 Fogh J, Holmgren NB and Ludovici PP: A review of cell culture contaminations. In Vitro *7*: 26-41, 1971.

255 Studzinski GP, Gierthy JF and Cholon JJ: An autoradiographic screening test for mycoplasmal contamination of mammalian cell cultures. In Vitro *8*: 466-472, 1973.

256 Uphoff CC, Drexler HG: Detecting mycoplasma contamination in cell cultures by polymerase chain reaction. Methods Mol Med *88*: 319-326, 2004.

257 Puck TT, Marcus PI and Cieciura SJ: Clonal growth of mammalian cells *in vitro*; growth characteristics of colonies from single HeLa cells with and without a feeder layer. J Exp Med *103*: 273-283, 1956.

258 Bancroft JD, Gamble M: Theory and practice of histological techniques. 6th Edition. Churchill Livingstone Elsevier, 2008.

259 Epstein ML and Gilula NB: A study of communication specificity between cells in culture. J Cell Biol *75*: 769-87, 1977.

260 Goodpasture C and Bloom SE: Visualization of nucleolar organizer regions im mammalian chromosomes using silver staining. Chromosoma *53*: 37-50, 1975.

261 Ayad SR and Delinassios JG: Virus mediated transfer of DNA from isolated nuclei to the cytoplasm and nucleus of hamster fibroblasts in culture. Differentiation *4*: 125-134, 1975.

262 Nestor SL and Bancroft JD: Enzyme histochemistry and its diagnostic applications. In: Theory and Practice of Histological Techniques. Edited by JD Bancroft and M. Gamble, pp. 405-432, Churchill Livingstone Elsevier, 2008.

263 Houston AH and McCarty LS: Carbonic anhydrase (acetazolamide-sensitive esterase) activity in the blood, gill and kidney of the thermally acclimated rainbow trout, Salmo gairdneri. J Exp Biol *73*: 15-27, 1978.

264 Iyer R, Barrese AA 3rd, Parakh S, Parker CN and Tripp BC: Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds. J Biomol Screen *11*: 782-791, 2006.

265 Gilmour KM: Perspectives on carbonic anhydrase. Comp Biochem Physiol A Mol Integr Physiol *157*: 193-197, 2010.

266 Role of immunohistochemical expression of ki-67 in adenocarcinoma of large intestine. *In*: Handbook of Immunohistochemistry and in situ Hybridization of Human Carcinomas, Vol. 4. Edited by M. A. Hayat, pp. 127-134, 2006, Elsevier Academic Press.

267 Huennekens FM, Vitols KS, Whiteley JM and Neff VG: *In*: Methods in Cancer Research. Edited by H. Busch, ed. 13, pp. 199-225, Academic Press New York, 1976.

268 Langlois NE, Eremin O and Heys SD: Apoptosis and prognosis in cancer: rationale and relevance. J R Coll Surg Edinb *45*: 211-219, 2000.

269 Saraste A and Pulkki K: Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res *45*: 528-537, 2000.

270 Langley RR and Fidler IJ: The seed and soil hypothesis revisited--the role of tumour-stroma interactions in metastasis to different organs. Int J Cancer *128*: 2527-2535, 2011.

271 Talmadge JE and Fidler IJ: AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 70: 5649-5669, 2010.

272 Marjanovic ND, Weinberg RA and Chaffer CL: Cell plasticity and heterogeneity in cancer. Clin Chem *59*: 168-179, 2013.

273 Augsten M: Cancer-associated fibroblasts as another polarized cell type of the tumour microenvironment. Front Oncol *4*: 62, 2014.

274 Rozenchan PB, Carraro DM, Brentani H, de Carvalho Mota LD, Bastos EP, e Ferreira EN, Torres CH, Katayama ML, Roela RA, Lyra EC, Soares FA, Folgueira MA, Góes JC and Brentani MM: Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts. Int J Cancer *125*: 2767-2777, 2009.

275 Durning P, Schor SL and Sellwood RA: Fibroblasts from patients with breast cancer show abnormal migratory behaviour *in vitro*. Lancet *2*: 890-892, 1984.

276 Klein-Goldberg A, Maman S and Witz IP: The role played by the microenvironment in site-specific metastasis. Cancer Lett *352*: 54-58, 2014.

277 Namba M, Fukushima F and Kimoto T: Effects of feeder layers made of human, mouse, hamster, and rat cells on the cloning efficiency of transformed human cells. In Vitro *18*: 469-475, 1982.

278 Polyak K, Haviv I and Campbell IG: Co-evolution of tumour cells and their microenvironments. Trends Genet *25*: 30-38, 2009.

279 Jia Z, Wang Y, Sawyers A, Yao H, Rahmatpanah F, Xia XQ, Xu Q, Pio R, Turan T, Koziol JA, Goodison S, Carpenter P, Wang-Rodriguez J, Simoneau A, Meyskens F, Sutton M, Lernhardt W, Beach T, Monforte J, McClelland M and Mercola D: Diagnosis of prostate cancer using differentially expressed genes in stroma. Cancer Res *71*: 2476-2487, 2011.

280 Maclean N and Hall BK: Cell commitment and differentiation. Cambridge University Press, Cambridge, UK, pp. 244, 1987.

281 Rejniak KA: Modelling the development of complex tissues using individual viscoelastic cells. In: Single-Cell-Based Models in Biology and Medicine. Edited by Anderson A, Chaplain M and Rejniak KA, pp. 301-323, Birkhauser-Verlag, Basel, Switzerland, 2007.

282 Feder JN, Assaraf YG, Seamer LC and Schimke RT: The pattern of dihydrofolate reductase expression through the cell cycle in rodent and human cultured cells. J Biol Chem *264*: 20583-20590, 1989.

283 Mariani BD, Slate DL and Schimke RT: S phase-specific synthesis of dihydrofolate reductase in Chinese hamster ovary cells. Proc Natl Acad Sci USA *78*: 4985-4989, 1981.

284 Burz C, Berindan-Neagoe I, Balacescu O and Irimie A: Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol *48*: 811-821, 2009.

285 Ghesquière B, Wong BW, Kuchnio A and Carmeliet P: Metabolism of stromal and immune cells in health and disease. Nature *511*: 167-176, 2014.

286 Coleman HG, Altini M and Groeneveld HT: Nucleolar organizer regions (AgNORs) in odontogenic cysts and ameloblastomas. J Oral Pathol *25*: 436-440, 1996.

287 Derenzini M: The AgNORs. Micron *31*: 117-120, 2000.

288 Trosko JE and Ruch RJ: Cell-cell communication in carcinogenesis. Front Biosci *3*: d208-36, 1998.

289 Rattigan YI, Patel BB, Ackerstaff E, Sukenick G, Koutcher JA, Glod JW and Banerjee D: Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumour cells in the tumour microenvironment. Exp Cell Res *318*: 326-335, 2012.

290 Mittelbrunn M and Sánchez-Madrid F: Intercellular communication: diverse structures for exchange of genetic information. Nat Rev Mol Cell Biol *13*: 328-335, 2012.

291 Polanska UM and Orimo A: Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol *228*: 1651-1657, 2013.

292 Murakami M, Ernsting MJ, Undzys E, Holwell N, Foltz WD and Li SD: Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res *73*: 4862-4871, 2013.

293 Vanpoucke G, Orr B, Grace OC, Chan R, Ashley GR, Williams K, Franco OE, Hayward SW and Thomson AA: Transcriptional profiling of inductive mesenchyme to identify molecules involved in prostate development and disease. Genome Biol *8*: R213, 2007.

294 Mueller L, Goumas FA, Affeldt M, Sandtner S, Gehling UM, Brilloff S, Walter J, Karnatz N, Lamszus K, Rogiers X and Broering DC: Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am J Pathol *171*: 1608-1618, 2007.

295 Fisher DT, Appenheimer MM and Evans SS: The two faces of IL-6 in the tumour microenvironment. Semin Immunol *26*: 38-47, 2014.

296 Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Löchner D and Birchmeier W: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol *113*: 173-185, 1991.

297 Schulte J, Weidig M, Balzer P, Richter P, Franz M, Junker K, Gajda M, Friedrich K, Wunderlich H, Östman A, Petersen I and Berndt A: Expression of the E-cadherin repressors Snail, Slug and Zeb1 in urothelial carcinoma of the urinary bladder: relation to stromal fibroblast activation and invasive behaviour of carcinoma cells. Histochem Cell Biol *138*: 847-860, 2012.

298 Froeling FE, Mirza TA, Feakins RM, Seedhar A, Elia G, Hart IR and Kocher HM: Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumour cells. Am J Pathol *175*: 636-48, 2009.

299 Angelucci C, Maulucci G, Lama G, Proietti G, Colabianchi A, Papi M, Maiorana A, De Spirito M, Micera A, Balzamino OB, Di Leone A, Masetti R and Sica G: Epithelial-Stromal Interactions in Human Breast Cancer: Effects on Adhesion, Plasma Membrane Fluidity and Migration Speed and Directness. PLoS One *7*: e50804, 2012.

300 Iacopino F, Angelucci C and Sica G: Interactions between normal human fibroblasts and human prostate cancer cells in a co-culture system. Anticancer Res *32*: 1579-1588, 2012.

301 Christofori G and Semb H: The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci *24*: 73-76, 1999.

302 Regulation of the E-cadherin adhesion complex in tumour cell migration and invasion. In: Cell Migration: Signalling and Mechanisms. Edited by Entschladen F. And Zänker K.S., pp. 120-135, 2010, Karger AG, Basel.

303 Rodriguez FJ, Lewis-Tuffin LJ and Anastasiadis PZ: E-cadherin's dark side: possible role in tumour progression. Biochim Biophys Acta *1826*: 23-31, 2012.

304 van Roy F: Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer *14*: 121-134, 2014.

305 O'Malley KJ, Eisermann K, Pascal LE, Parwani AV, Majima T, Graham L, Hrebinko K, Acquafondata M, Stewart NA, Nelson JB, Yoshimura N and Wang Z: Proteomic analysis of patient tissue reveals PSA protein in the stroma of benign prostatic hyperplasia. Prostate *74*: 892-900, 2014.

306 Nagaraju GP and Sharma D: Anti-cancer role of SPARC, an inhibitor of adipogenesis. Cancer Treat Rev *37*: 559-566, 2011.

307 Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, Mulvihill MM, Luo K and Nomura DK: Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. Proc Natl Acad Sci USA *110*: 14912-14917, 2013.

308 Zhao M, Dumur CI, Holt SE, Beckman MJ and Elmore LW: Multipotent adipose stromal cells and breast cancer development: Think globally, act locally. Mol Carcinog *49*: 923-927, 2010.

309 Lehmann GM, Woeller CF, Pollock SJ, O'Loughlin CW, Gupta S, Feldon SE and Phipps RP: Novel anti-adipogenic activity produced by human fibroblasts. Am J Physiol Cell Physiol *299*: C672-81, 2010.

310 Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, Majed B, Wang YY, Meulle A, Salles B, Le Gonidec S, Garrido I, Escourrou G, Valet P and Muller C: Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res *71*: 2455-2465, 2011.

311 Hasebe T, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, Sasajima Y, Kinoshita T and Tsuda H: Atypical tumour-stromal fibroblasts in invasive ductal carcinoma of the breast. Am J Surg Pathol *35*: 325-336, 2011.

312 Monis B and Weinberg T: Cytochemical study of esterase activity of human neoplasms and stromal macrophages. Cancer *14*: 369-377, 1961.

313 Frost JL and Brandes D: Nonspecific esterases in rat prostatic epithelial cells. J Histochem Cytochem *15*: 589-595, 1967.

314 Verpoorte JA, Mehta S and Edsall JT: Esterase activities of human carbonic anhydrases B and C. J Biol Chem *242*: 4221-4229, 1967.

315 De Duve C: The lysosome concept. *In*: Ciba Foundation Symposium on Lysosomes. Edited by AVS DeReuck and MP Cameron, Little, Brown & Co., Boston, MA, USA, pp. 1-28, 1963.

316 Nakao M, Ishii G, Nagai K, Kawase A, Kenmotsu H, Kon-No H, Hishida T, Nishimura M, Yoshida J and Ochiai A: Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer *115*: 2732-2743, 2009.

317 Svastova E, Witarski W, Csaderova L, Kosik I, Skvarkova L, Hulikova A, Zatovicova M, Barathova M, Kopacek J, Pastorek J and Pastorekova S: Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. J Biol Chem *287*: 3392-3402, 2012.

318 Novotny A, Ryberg K, Heiman Ullmark J, Nilsson L, Khorram-Manesh A, Nordgren S, Delbro DS and Nylund G: Is acetylcholine a signaling molecule for human colon cancer progression? Scand J Gastroenterol *46*: 446-455, 2011.

319 Hübner MR and Spector DL: Chromatin dynamics. Annu Rev Biophys *39*: 471-489, 2010.

320 de Las Heras JI, Batrakou DG and Schirmer EC: Cancer biology and the nuclear envelope: a convoluted relationship. Semin Cancer Biol *23*: 125-137, 2013.

321 Reddy KL and Feinberg AP: Higher order chromatin organization in cancer. Semin Cancer Biol *23*: 109-115, 2013.

322 Meaburn KJ and Misteli T: Cell biology: chromosome territories. Nature *445*: 379-781, 2007.

323 Fujita T, Epperly MW, Zou H, Greenberger JS and Wan Y: Regulation of the anaphase-promoting complex-separase cascade by transforming growth factor-beta modulates mitotic progression in bone marrow stromal cells. Mol Biol Cell *19*: 5446-5455, 2008.

324 Prins HJ , Rozemuller H, Vonk-Griffioen S, Verweij VG, Dhert WJ, Slaper-Cortenbach IC and Martens AC: Bone-forming capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as substitute for fetal bovine serum. Tissue Eng Part A *15*: 3741-3751, 2009.

325 Huang HI, Chen SK, Ling QD, Chien CC, Liu HT and Chan SH: Multilineage differentiation potential of fibroblast-like stromal cells derived from human skin. Tissue Eng Part A *16*: 1491-1501, 2010.

326 Xu J, Liu X, Chen J, Zacharek A, Cui X, Savant-Bhonsale S, Chopp M and Liu Z: Cell-cell interaction promotes rat marrow stromal cell differentiation into endothelial cell via activation of TACE/TNF-alpha signaling. Cell Transplant *19*: 43-53, 2010.

327 Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, Möller T, Pesonen S, Hemminki A, Hamerlik P, Drescher C, Urban N, Bartek J and Lieber A.: Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One *6*: e16186, 2011.

328 Xue Y, Ouyang K, Huang J, Zhou Y, Ouyang H, Li H, Wang G, Wu Q, Wei C, Bi Y, Jiang L, Cai Z, Sun H, Zhang K, Zhang Y, Chen J and Fu XD: Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. Cell *152*: 82-96, 2013.

329 Reddy LA, Mikesh L, Moskulak C, Harvey J, Sherman N, Zigrino P, Mauch C and Fox JW: Host Response to Human Breast Invasive Ductal Carcinoma (IDC) as Observed by Changes in the Stromal Proteome. J Proteome Res *13*: 4739-4751, 2014.

330 Coulson-Thomas YM, Ferreira TG, Norton AL, Kao W W-Y, Nader HB and Coulson-Thomas VJ: The role of proteoglycans in the reactive stroma on tumour growth and progression. Histol Histopathol *30*: 33-41, 2015.

331 Bexell D, Scheding S and Bengzon J: Toward brain tumour gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther *18*: 1067-1075, 2010.

332 Shah K: Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev *64*: 739-748, 2012.

333 Ostman A: The tumour microenvironment controls drug sensitivity. Nat Med *18*: 1332-1334, 2012.

334 Fang H and Declerck YA: Targeting the tumour micro-environment: from understanding pathways to effective clinical trials. Cancer Res *73*: 4965-4977, 2013.

335 Coussens LM, Zitvogel L and Palucka AK: Neutralizing tumour-promoting chronic inflammation: a magic bullet? Science *339*: 286-291, 2013.

336 Dembinski JL, Wilson SM, Spaeth EL, Studeny M, Zompetta C, Samudio I, Roby K, Andreeff M and Marini FC: Tumour stroma engraftment of gene-modified mesenchymal stem cells as anti-tumour therapy against ovarian cancer. Cytotherapy *15*: 20-32, 2013.

337 Lunardi S, Muschel RJ and Brunner TB: The stromal compartments in pancreatic cancer: are there any therapeutic targets? Cancer Lett *343*: 147-155, 2014.

338 Knelson EH, Gaviglio AL, Nee JC, Starr MD, Nixon AB, Marcus SG and Blobe GC: Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. J Clin Invest *124*: 3016-3031, 2014.

339 Ahn JO, Chae JS, Coh YR, Jung WS, Lee HW, Shin IS, Kang SK and Youn HY: Human adipose tissue-derived mesenchymal stem cells inhibit T-cell lymphoma growth *in vitro* and *in vivo*. Anticancer Res *34*: 4839-4847, 2014.

340 Serakinci N, Fahrioglu U and Christensen R: Mesenchymal stem cells, cancer challenges and new directions. Eur J Cancer *50*: 1522-1530, 2014.

341 Narunsky L, Oren R, Bochner F and Neeman M: Imaging aspects of the tumour stroma with therapeutic implications. Pharmacol Ther *141*: 192-208, 2014.

342 Sirica AE and Gores GJ: Desmoplastic stroma and cholangio-carcinoma: clinical implications and therapeutic targeting. Hepatology *59*: 2397-2402, 2014

343 Yamada KM and Cukierman E: Modeling tissue morphogenesis and cancer in 3D. Cell *130*: 601-610, 2007.

344 Österholm C, Lu N, Lidén Å, Karlsen TV, Gullberg D, Reed RK and Kusche-Gullberg M: Fibroblast EXT1-levels influence tumour cell proliferation and migration in composite spheroids. PLoS One *7*: e41334, 2012.

345 Derda R, Tang SK, Laromaine A, Mosadegh B, Hong E, Mwangi M, Mammoto A, Ingber DE and Whitesides GM: Multizone paper platform for 3D cell cultures. PLoS One *6*: e18940, 2011.

346 Tome Y, Uehara F, Mii S, Yano S, Zhang L, Sugimoto N, Maehara H, Bouvet M, Tsuchiya H, Kanaya F and Hoffman RM: 3-dimensional tissue is formed from cancer cells *in vitro* on Gelfoam®, but not on MatrigelTM. J Cell Biochem *115*: 1362-1367, 2014.